1
|
Kada Mohammed S, Dabakuyo Yonli TS, Desmoulins I, Manguem Kamga A, Jankowski C, Padeano MM, Loustalot C, Costaz H, Causeret S, Peignaux K, Rouffiac M, Coutant C, Arnould L, Ladoire S. Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry. Breast Cancer Res Treat 2023; 197:377-385. [PMID: 36417042 PMCID: PMC9823085 DOI: 10.1007/s10549-022-06807-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2022] [Accepted: 10/30/2022] [Indexed: 11/24/2022]
Abstract
PURPOSE The prognosis of local invasive recurrence (LIR) after prior carcinoma in situ (CIS) of the breast has not been widely studied and existing data are conflicting, especially considering the specific prognosis of this entity, compared to de novo invasive breast cancer (de novo IBC) and with LIR after primary IBC. METHODS We designed a retrospective study using data from the specialized Côte d'Or Breast and Gynecological cancer registry, between 1998 and 2015, to compare outcomes between 3 matched groups of patients with localized IBC: patients with LIR following CIS (CIS-LIR), patients with de novo IBC (de novo IBC), and patients with LIR following a first IBC (IBC-LIR). Distant relapse-free (D-RFS), overall survival (OS), clinical, and treatment features between the 3 groups were studied. RESULTS Among 8186 women initially diagnosed with IBC during our study period, we retrieved and matched 49 CIS-LIR to 49 IBC, and 46 IBC-LIR patients. At diagnosis, IBC/LIR in the 3 groups were mainly stage I, grade II, estrogen receptor-positive, and HER2 negative. Metastatic diseases at diagnosis were higher in CIS-LIR group. A majority of patients received adjuvant systemic treatment, with no statistically significant differences between the 3 groups. There was no significant difference between the 3 groups in terms of OS or D-RFS. CONCLUSION LIR after CIS does not appear to impact per se on survival of IBC.
Collapse
Affiliation(s)
- Samia Kada Mohammed
- grid.414153.60000 0000 8897 490XDepartment of Gynaecology and Obstetrics, Assistance Publique des Hôpitaux de Paris (APHP), Jean Verdier Hospital, Avenue du 14 Juillet, 93140 Bondy, France
| | - Tienhan Sandrine Dabakuyo Yonli
- Breast and Gynaecologic Cancer Registry of Côte d’Or, Epidemiology and Quality of Life Research Unit, Georges-François Leclerc Comprehensive Cancer Centre-UNICANCER, 1 rue du Professeur Marion, 21000 Dijon, France ,INSERM U1231, 21000 Dijon, France
| | - Isabelle Desmoulins
- Department of Medical Oncology, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000 Dijon, France
| | - Ariane Manguem Kamga
- Breast and Gynaecologic Cancer Registry of Côte d’Or, Epidemiology and Quality of Life Research Unit, Georges-François Leclerc Comprehensive Cancer Centre-UNICANCER, 1 rue du Professeur Marion, 21000 Dijon, France ,INSERM U1231, 21000 Dijon, France
| | - Clémentine Jankowski
- Department of Surgery, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000 Dijon, France
| | - Marie-Martine Padeano
- Department of Surgery, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000 Dijon, France
| | - Catherine Loustalot
- Department of Surgery, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000 Dijon, France
| | - Hélène Costaz
- Department of Surgery, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000 Dijon, France
| | - Sylvain Causeret
- Department of Surgery, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000 Dijon, France
| | - Karine Peignaux
- Department of Radiotherapy, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000 Dijon, France
| | - Magali Rouffiac
- Department of Radiotherapy, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000 Dijon, France
| | - Charles Coutant
- Department of Surgery, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000 Dijon, France ,grid.5613.10000 0001 2298 9313University of Burgundy-Franche Comté, 21000 Dijon, France
| | - Laurent Arnould
- Unit of Pathology, Department of Tumour Biology and Pathology, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000 Dijon, France
| | - Sylvain Ladoire
- INSERM U1231, 21000 Dijon, France ,Department of Medical Oncology, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000 Dijon, France ,grid.5613.10000 0001 2298 9313University of Burgundy-Franche Comté, 21000 Dijon, France
| |
Collapse
|
2
|
Fauconnier MB, Burnier P, Jankowski C, Loustalot C, Coutant C, Vincent L. Comparison of postoperative complications following conventional latissimus dorsi flap versus muscle-sparing latissimus dorsi flap breast reconstruction. J Plast Reconstr Aesthet Surg 2022; 75:3653-3663. [DOI: 10.1016/j.bjps.2022.06.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Revised: 05/31/2022] [Accepted: 06/21/2022] [Indexed: 11/30/2022]
|
3
|
Baudry AS, Yakimova S, Congard A, Untas A, Guiu S, Lefeuvre-Plesse C, Loustalot C, Guillemet C, Segura-Djezzar C, Savoye AM, Coussy F, Frenel JS, Vanlemmens L, Christophe V. Adjustment of young women with breast cancer after chemotherapy: A mediation model of emotional competence via emotional distress. Psychooncology 2022; 31:848-855. [PMID: 34989072 DOI: 10.1002/pon.5876] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Revised: 12/15/2021] [Accepted: 12/27/2021] [Indexed: 11/11/2022]
Abstract
OBJECTIVE Emotional competence (EC) is considered a substantial resource in the adjustment of cancer patients, especially via its effect on anxiety and depression symptoms. This research aimed at assessing the impact of intrapersonal EC in young women (≤45 years) with breast cancer (YWBC) on their specific quality of life (i.e. subjective experience related to daily difficulties and perceived repercussions of the disease and treatments) related to chemotherapy, via anxiety and depression symptoms. METHODS Two hundred fifty YWBC from 24 French centers completed a self-reported questionnaire after diagnosis (T1) and after the chemotherapy phase (T2), comprising the Young Women Breast Cancer Inventory, the Profile of EC and the Hospital Anxiety and Depression Scale. The indirect effect of EC (T1) on subjective experience (T2) via anxiety and depression symptoms (T2) was tested using regressions and the Macro PROCESS. RESULTS Emotional competence predicted fewer anxiety and depression symptoms at T1 and T2, and a better subjective experience at T2 via fewer anxiety and depression symptoms. Depression symptoms appeared to be a stronger mediator than anxiety symptoms on four dimensions (Support from close relatives, feeling of couple cohesion, body image and sexuality, management of children and everyday life), whereas anxiety symptoms appeared to be a stronger mediator on two dimensions (negative affectivity and apprehension about the future, deterioration of relationships). CONCLUSIONS These results support the importance of developing psycho-affective interventions to reinforce the EC of YWBC during chemotherapy in order to facilitate the cognitive and emotional processes necessary for a better adjustment and subjective experience.
Collapse
Affiliation(s)
- Anne-Sophie Baudry
- Pôle Cancérologie et Spécialités Médicales - Centre Hospitalier de Valenciennes, Valenciennes, France.,Univ. Lille, CNRS, UMR 9193 - SCALab - Sciences Cognitives et Sciences Affectives, Lille, France.,Human and Social Sciences Department - Centre Léon Bérard, Lyon, France
| | - Sonya Yakimova
- Aix-Marseille Université, Centre de Recherche PsyCLÉ, EA 3273, Marseille, France
| | - Anne Congard
- Nantes Université, Laboratoire de Psychologie des Pays de la Loire, LPPL, EA 4638, Nantes, France
| | - Aurélie Untas
- Université de Paris, Laboratoire de Psychopathologie et Processus de Santé, Boulogne-Billancourt, France
| | - Séverine Guiu
- Department of Medical Oncology, ICM, Montpellier, France.,IRCM, INSERM, Université Montpellier, ICM, Montpellier, France
| | | | | | | | | | | | - Florence Coussy
- Département d'oncologie Médicale, Institut Curie Hôpital René Huguenin, Saint-Cloud, France
| | | | | | - Véronique Christophe
- Univ. Lille, CNRS, UMR 9193 - SCALab - Sciences Cognitives et Sciences Affectives, Lille, France.,Human and Social Sciences Department - Centre Léon Bérard, Lyon, France
| |
Collapse
|
4
|
Bergeron A, MacGrogan G, Bertaut A, Ladoire S, Arveux P, Desmoulins I, Bonnefoi H, Loustalot C, Auriol S, Beltjens F, Degrolard-Courcet E, Charon-Barra C, Richard C, Boidot R, Arnould L. Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations. Mod Pathol 2021; 34:1282-1296. [PMID: 33753865 PMCID: PMC8216909 DOI: 10.1038/s41379-021-00742-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Revised: 01/17/2021] [Accepted: 01/19/2021] [Indexed: 12/12/2022]
Abstract
Primary triple-negative invasive lobular breast carcinomas (TN-ILCs), which do not express hormone receptors and HER2 at diagnosis, are rare and poorly known. In this study, we analyzed the largest TN-ILC series ever reported in the literature, in comparison to phenotypically similar breast tumor subtypes: triple-negative invasive ductal carcinoma (TN-IDC) and hormone receptor-positive invasive lobular carcinoma (HR + ILC). All primary TN-ILCs registered in our database between 2000 and 2018 (n = 38) were compared to tumors from control groups, matched by stage and Elston/Ellis grade, with regard to clinical, pathologic, and immunohistochemical characteristics. A comparative molecular analysis (whole-exome and RNA sequencing using next-generation technology) was also performed. We found that TN-ILC patients were older than those with HR + ILC (P = 0.002) or TN-IDC (P < 0.001). Morphologically, TN-ILCs had aggressive phenotypes, with more pleomorphism (P = 0.003) and higher nuclear grades than HR + ILCs (P = 0.009). Immunohistochemistry showed that TN-ILCs less frequently expressed basal markers (CK5/6, EGFR and SOX10) than TN-IDCs (P < 0.001), while androgen receptor (AR) positivity was more prevalent (P < 0.001). Survival curves analysis did not show differences between TN-ILC and TN-IDC patients, while overall and distant metastasis-free survival were significantly worse compared to those with HR + ILCs (P = 0.047 and P = 0.039, respectively). At a molecular level, we found that TN-ILCs had particular transcriptomic profiles, characterized by increased AR signaling, and associated with frequent alterations in the PI3K network and ERBB2. Interestingly, whole-exome analysis also identified three specific recurrent ESRRA hotspot mutations in these tumors, which have never been described in breast cancer to date and which were absent in the other two tumor subtypes. Our findings highlight that TN-ILC is a unique aggressive breast cancer associated with elderly age, which belong to the luminal androgen receptor subtype as determined by immunohistochemistry and transcriptomic profiling. Moreover, it harbors specific molecular alterations (PI3K, ERBB2 and ESRRA) which may pave the way for new targeted therapeutic strategies.
Collapse
Affiliation(s)
- Anthony Bergeron
- Unit of Pathology, Department of Biology and Pathology of the Tumors, Centre Georges-François Leclerc, Dijon, France.
| | - Gaëtan MacGrogan
- Department of Biopathology, Institut Bergonié, Bordeaux, France
- INSERM U1218, Bordeaux, France
| | - Aurélie Bertaut
- Unit of Methodology and Biostatistics, Centre Georges-François Leclerc, Dijon, France
| | - Sylvain Ladoire
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
- INSERM U1231, Dijon, France
- University of Burgundy-Franche Comté, Dijon, France
| | - Patrick Arveux
- Department of Epidemiology, Centre Georges-François Leclerc, Dijon, France
| | - Isabelle Desmoulins
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
| | - Hervé Bonnefoi
- INSERM U1218, Bordeaux, France
- Department of Medical Oncology, Institut Bergonié, Bordeaux, France
- University of Bordeaux, Bordeaux, France
| | | | - Sophie Auriol
- Department of Surgery, Institut Bergonié, Bordeaux, France
| | - Françoise Beltjens
- Unit of Pathology, Department of Biology and Pathology of the Tumors, Centre Georges-François Leclerc, Dijon, France
| | - Emilie Degrolard-Courcet
- Unit of Pathology, Department of Biology and Pathology of the Tumors, Centre Georges-François Leclerc, Dijon, France
| | - Céline Charon-Barra
- Unit of Pathology, Department of Biology and Pathology of the Tumors, Centre Georges-François Leclerc, Dijon, France
| | - Corentin Richard
- Unit of Molecular Pathology, Department of Biology and Pathology of the Tumors, Centre Georges-François Leclerc, Dijon, France
| | - Romain Boidot
- Unit of Molecular Pathology, Department of Biology and Pathology of the Tumors, Centre Georges-François Leclerc, Dijon, France
| | - Laurent Arnould
- Unit of Pathology, Department of Biology and Pathology of the Tumors, Centre Georges-François Leclerc, Dijon, France
- INSERM U1231, Dijon, France
| |
Collapse
|
5
|
Nambot S, Sawka C, Bertolone G, Cosset E, Goussot V, Derangère V, Boidot R, Baurand A, Robert M, Coutant C, Loustalot C, Thauvin-Robinet C, Ghiringhelli F, Lançon A, Populaire C, Damette A, Collonge-Rame MA, Meunier-Beillard N, Lejeune C, Albuisson J, Faivre L. Incidental findings in a series of 2500 gene panel tests for a genetic predisposition to cancer: Results and impact on patients. Eur J Med Genet 2021; 64:104196. [PMID: 33753322 DOI: 10.1016/j.ejmg.2021.104196] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2020] [Revised: 02/02/2021] [Accepted: 03/14/2021] [Indexed: 10/21/2022]
Abstract
With next generation sequencing, physicians are faced with more complex and uncertain data, particularly incidental findings (IF). Guidelines for the return of IF have been published by learned societies. However, little is known about how patients are affected by these results in a context of oncogenetic testing. Over 4 years, 2500 patients with an indication for genetic testing underwent a gene cancer panel. If an IF was detected, patients were contacted by a physician/genetic counsellor and invited to take part in a semi-structured interview to assess their understanding of the result, the change in medical care, the psychological impact, and the transmission of results to the family. Fourteen patients (0.56%) were delivered an IF in a cancer predisposition gene (RAD51C, PMS2, SDHC, RET, BRCA2, CHEK2, CDKN2A, CDH1, SUFU). Two patients did not collect the results and another two died before the return of results. Within the 10 patients recontacted, most of them reported surprise at the delivery of IF, but not anxiety. The majority felt they had chosen to obtain the result and enough information to understand it. They all initiated the recommended follow-up and did not regret the procedure. Information regarding the IF was transmitted to their offspring but siblings or second-degree relatives were not consistently informed. No major adverse psychological events were found in our experience. IF will be inherent to the development of sequencing, even for restricted gene panels, so it is important to increase our knowledge on the impact of such results in different contexts.
Collapse
Affiliation(s)
- S Nambot
- Centre de Génétique, FHU TRANSLAD, Institut GIMI, CHU Dijon, F-21000, Dijon, France; CGFL, Unité D'oncogénétique et Institut GIMI, F-21000, Dijon, France.
| | - C Sawka
- Centre de Génétique, FHU TRANSLAD, Institut GIMI, CHU Dijon, F-21000, Dijon, France; CGFL, Unité D'oncogénétique et Institut GIMI, F-21000, Dijon, France
| | - G Bertolone
- Centre de Génétique, FHU TRANSLAD, Institut GIMI, CHU Dijon, F-21000, Dijon, France; CGFL, Unité D'oncogénétique et Institut GIMI, F-21000, Dijon, France
| | - E Cosset
- CGFL, Unité D'oncogénétique et Institut GIMI, F-21000, Dijon, France
| | - V Goussot
- Platform of Transfer in Cancer Biology, Department of Biology and Pathology of Tumours, Centre Georges-François Leclerc, Unicancer, F-21000, Dijon, France
| | - V Derangère
- Platform of Transfer in Cancer Biology, Department of Biology and Pathology of Tumours, Centre Georges-François Leclerc, Unicancer, F-21000, Dijon, France
| | - R Boidot
- Platform of Transfer in Cancer Biology, Department of Biology and Pathology of Tumours, Centre Georges-François Leclerc, Unicancer, F-21000, Dijon, France; CNRS, 6302 Unit, Dijon, France
| | - A Baurand
- Centre de Génétique, FHU TRANSLAD, Institut GIMI, CHU Dijon, F-21000, Dijon, France; CGFL, Unité D'oncogénétique et Institut GIMI, F-21000, Dijon, France
| | - M Robert
- Centre de Génétique, FHU TRANSLAD, Institut GIMI, CHU Dijon, F-21000, Dijon, France
| | - C Coutant
- Département de Chirurgie, Centre Georges François Leclerc, F-21000, Dijon, France
| | - C Loustalot
- Département de Chirurgie, Centre Georges François Leclerc, F-21000, Dijon, France
| | - C Thauvin-Robinet
- Centre de Génétique, FHU TRANSLAD, Institut GIMI, CHU Dijon, F-21000, Dijon, France
| | - F Ghiringhelli
- Platform of Transfer in Cancer Biology, Department of Biology and Pathology of Tumours, Centre Georges-François Leclerc, Unicancer, F-21000, Dijon, France; Département D'oncologie Médicale, Centre Georges François Leclerc, Dijon, France; Centre de Recherche INSERM LNC-UMR123, Université de Bourgogne Franche-Comté, F-21000, Dijon, France
| | - A Lançon
- CGFL, Unité D'oncogénétique et Institut GIMI, F-21000, Dijon, France
| | - C Populaire
- Service Génétique et Biologie Du Développement-Histologie, CHU Hôpital Saint-Jacques, Besançon, France
| | - A Damette
- Service Génétique et Biologie Du Développement-Histologie, CHU Hôpital Saint-Jacques, Besançon, France
| | - M A Collonge-Rame
- Service Génétique et Biologie Du Développement-Histologie, CHU Hôpital Saint-Jacques, Besançon, France
| | - N Meunier-Beillard
- INSERM, CIC1432, Module épidémiologie Clinique, Dijon, France; Centre Hospitalier Universitaire Dijon-Bourgogne, Centre D'investigation Clinique, Module épidémiologie Clinique/essais Cliniques, Dijon, France
| | - C Lejeune
- Centre de Recherche INSERM LNC-UMR123, Université de Bourgogne Franche-Comté, F-21000, Dijon, France; INSERM, CIC1432, Module épidémiologie Clinique, Dijon, France; Centre Hospitalier Universitaire Dijon-Bourgogne, Centre D'investigation Clinique, Module épidémiologie Clinique/essais Cliniques, Dijon, France
| | - J Albuisson
- Platform of Transfer in Cancer Biology, Department of Biology and Pathology of Tumours, Centre Georges-François Leclerc, Unicancer, F-21000, Dijon, France; Centre de Recherche INSERM LNC-UMR123, Université de Bourgogne Franche-Comté, F-21000, Dijon, France
| | - L Faivre
- Centre de Génétique, FHU TRANSLAD, Institut GIMI, CHU Dijon, F-21000, Dijon, France; CGFL, Unité D'oncogénétique et Institut GIMI, F-21000, Dijon, France.
| |
Collapse
|
6
|
Beltjens F, Molly D, Bertaut A, Richard C, Desmoulins I, Loustalot C, Charon-Barra C, Courcet E, Bergeron A, Ladoire S, Jankowski C, Boidot R, Arnould L. ER-/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer. Int J Cancer 2021; 149:200-213. [PMID: 33634878 DOI: 10.1002/ijc.33539] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Revised: 01/26/2021] [Accepted: 02/12/2021] [Indexed: 12/17/2022]
Abstract
Determining the status of steroid hormone receptors [oestrogen (ER) and progesterone receptors (PR)] is a crucial part of the breast cancer workup. Thereby, breast cancers can be classified into four subtypes. However, the existence of ER-/PR+ tumours, often reported to be ill-classified due to technical errors, remains controversial. In order to address this controversy, we reviewed the hormone receptor status of 49 breast tumours previously classified as ER-/PR+ by immunohistochemistry, and compared clinical, pathological and molecular characteristics of confirmed ER-/PR+ tumours with those of ER+ and triple-negative tumours. We unequivocally confirmed the ER-/PR+ status in 27 of 49 tumours (0.3% of all breast cancers diagnosed in our institution between 2000 and 2014). We found that ER-/PR+ were morphologically and histologically similar to triple-negative tumours, but very distinct from ER+ tumours, with more aggressive phenotypes and more frequent basal marker expression than the latter. On the molecular level, RNA sequencing revealed different gene expression profiles between the three groups. Of particular interest, several genes controlled by the suppressor of zest 12 (SUZ12) were upregulated in ER-/PR+ tumours. Overall, our results confirm that ER-/PR+ breast cancers are an extremely rare but 'real' tumour subtype that requires careful diagnosis and has distinct features warranting different responsiveness to therapies and different clinical outcomes. Studies on larger cohorts are needed to further characterise these tumours. The likely involvement of SUZ12 in their biology is an interesting finding which may - in a long run - give rise to the development of new therapeutic alternatives.
Collapse
Affiliation(s)
- Françoise Beltjens
- Department of Tumour Biology and Pathology, Pathology Unit, Centre Georges-François Leclerc, Dijon, France
| | | | - Aurélie Bertaut
- Methodology and Biostatistics Unit, Centre Georges-François Leclerc, Dijon, France
| | - Corentin Richard
- Department of Tumour Biology and Pathology, Molecular Biology Unit, Centre Georges-François Leclerc, Dijon, France
| | - Isabelle Desmoulins
- Department of Clinical Oncology, Centre Georges-François Leclerc, Dijon, France
| | - Catherine Loustalot
- Department of Surgical Oncology, Centre Georges-François Leclerc, Dijon, France
| | - Céline Charon-Barra
- Department of Tumour Biology and Pathology, Pathology Unit, Centre Georges-François Leclerc, Dijon, France
| | - Emilie Courcet
- Department of Tumour Biology and Pathology, Pathology Unit, Centre Georges-François Leclerc, Dijon, France
| | - Anthony Bergeron
- Department of Tumour Biology and Pathology, Pathology Unit, Centre Georges-François Leclerc, Dijon, France
| | - Sylvain Ladoire
- Department of Clinical Oncology, Centre Georges-François Leclerc, Dijon, France
| | | | - Romain Boidot
- Department of Tumour Biology and Pathology, Molecular Biology Unit, Centre Georges-François Leclerc, Dijon, France
| | - Laurent Arnould
- Department of Tumour Biology and Pathology, Pathology Unit, Centre Georges-François Leclerc, Dijon, France
| |
Collapse
|
7
|
Costaz H, Bendifallah S, Raimond E, Jankowski C, Dridi S, Lavoué V, Collinet P, Ouldamer L, Touboul C, Bricou A, Padeano MM, Loustalot C, Graesslin O, Ballester M, Coutant C. Impact of non-compliance with guidelines in early type 1 endometrial cancers management, study from FRANCOGYN group. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.5587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5587 Background: To standardize surgical practices, ESMO-ESGO-ESTRO consensus conference published in 2016 new guidelines on the management of endometrial cancer. The main objective of this study was to evaluate the impact of non-compliance with current surgical guidelines on disease-free survival and overall survival. Methods: 852 patients with presumptive stage I and II type 1 endometrial cancer were included in a multicenter retrospective study, conducted between January 2000 and November 2015. The main objective of this study was to evaluate the impact of non-compliance with current surgical recommendations on overall survival and disease-free survival. Results: Our study shows that 34.3% of patients (n = 292) did not benefit from optimal surgical treatment. These patients did not have a lombo-aortic lymphadenectomy (LAL) and were at high risk of recurrence. There is a significant difference in disease-free survival in favor of patients undergoing surgery according to the recommendations, (Hazard Ratio (HR): 0.37 (Confidence interval (95% CI): 0.26-0.54), p < 0.001). In multivariate analysis, optimal surgical procedure performance is an independent factor for disease-free survival with HR at 2.04 (95% CI: 1.14-3.68), p = 0.01. There is a significant difference in overall survival in favor of patients undergoing surgery according to the recommendations, (HR: 0.31 (95% CI): 0.19-0.49), p < 0.001. In multivariate analysis, there is a trend toward significance with HR: 2.24 (95% CI: 1-5.05), p = 0.05. Older patients, patients with a larger BMI, patients with no indication of LAL at the preoperative ESMO classification, and no node involvement in are factors contributing to the decision of not to perform a LAL: p < 0.001, p = 0.03, p < 0.001 and p < 0.001 respectively. Conclusions: This study shows that patients with early type 1 endometrial cancer have improved recurrence-free survival and a statistical trend for an increased overall survival when recommended surgery is performed. Despite the current context of therapeutic de-escalation, we must strive to achieve the recommended optimal surgery, even if it requires secondary surgical revision, to avoid underestimation of patients with a poorer prognosis. To improve endometrial cancers management, amelioration of the preoperative assessment by increasing the sensitivity of emboli detection should be considered.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Catherine Loustalot
- Department of Surgery/Georges François Leclerc Comprehensive Cancer Care Centre, Dijon, France
| | | | | | | |
Collapse
|
8
|
Hemming ML, Lawlor MA, Andersen JL, Hagan T, Chipashvili O, Scott TG, Raut CP, Sicinska E, Armstrong SA, Demetri GD, Bradner JE, Ganz PA, Tomlinson G, Olopade OI, Couch FJ, Wang X, Lindor NM, Pankratz VS, Radice P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Viel A, Allavena A, Dall'Olio V, Peterlongo P, Szabo CI, Zikan M, Claes K, Poppe B, Foretova L, Mai PL, Greene MH, Rennert G, Lejbkowicz F, Glendon G, Ozcelik H, Andrulis IL, Thomassen M, Gerdes AM, Sunde L, Cruger D, Birk Jensen U, Caligo M, Friedman E, Kaufman B, Laitman Y, Milgrom R, Dubrovsky M, Cohen S, Borg A, Jernström H, Lindblom A, Rantala J, Stenmark-Askmalm M, Melin B, Nathanson K, Domchek S, Jakubowska A, Lubinski J, Huzarski T, Osorio A, Lasa A, Durán M, Tejada MI, Godino J, Benitez J, Hamann U, Kriege M, Hoogerbrugge N, van der Luijt RB, van Asperen CJ, Devilee P, Meijers-Heijboer EJ, Blok MJ, Aalfs CM, Hogervorst F, Rookus M, Cook M, Oliver C, Frost D, Conroy D, Evans DG, Lalloo F, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Hodgson S, Morrison PJ, Porteous ME, Walker L, Kennedy MJ, Dorkins H, Peock S, Godwin AK, Stoppa-Lyonnet D, de Pauw A, Mazoyer S, Bonadona V, Lasset C, Dreyfus H, Leroux D, Hardouin A, Berthet P, Faivre L, Loustalot C, Noguchi T, Sobol H, Rouleau E, Nogues C, Frénay M, Vénat-Bouvet L, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D, Singer CF, Dressler AC, Gschwantler-Kaulich D, Pfeiler G, Hansen TVO, Jønson L, Agnarsson BA, Kirchhoff T, Offit K, Devlin V, Dutra-Clarke A, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov E, Tihomirova L, Blanco I, Lazaro C, Ramus SJ, Sucheston L, Karlan BY, Gross J, Schmutzler R, Wappenschmidt B, Engel C, Meindl A, Lochmann M, Arnold N, Heidemann S, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Kast K, Schönbuchner I, Caldes T, de la Hoya M, Aittomäki K, Nevanlinna H, Simard J, Spurdle AB, Holland H, Chen X, Platte R, Chenevix-Trench G, Easton DF. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Res 2019. [PMID: 18483246 DOI: 10.1158/0008-5472] [Citation(s) in RCA: 655] [Impact Index Per Article: 131.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Gastrointestinal stromal tumor (GIST) is a mesenchymal neoplasm characterized by activating mutations in the related receptor tyrosine kinases KIT and PDGFRA. GIST relies on expression of these unamplified receptor tyrosine kinase (RTK) genes through a large enhancer domain, resulting in high expression levels of the oncogene required for tumor growth. Although kinase inhibition is an effective therapy for many patients with GIST, disease progression from kinase-resistant mutations is common and no other effective classes of systemic therapy exist. In this study, we identify regulatory regions of the KIT enhancer essential for KIT gene expression and GIST cell viability. Given the dependence of GIST upon enhancer-driven expression of RTKs, we hypothesized that the enhancer domains could be therapeutically targeted by a BET bromodomain inhibitor (BBI). Treatment of GIST cells with BBIs led to cell-cycle arrest, apoptosis, and cell death, with unique sensitivity in GIST cells arising from attenuation of the KIT enhancer domain and reduced KIT gene expression. BBI treatment in KIT-dependent GIST cells produced genome-wide changes in the H3K27ac enhancer landscape and gene expression program, which was also seen with direct KIT inhibition using a tyrosine kinase inhibitor (TKI). Combination treatment with BBI and TKI led to superior cytotoxic effects in vitro and in vivo, with BBI preventing tumor growth in TKI-resistant xenografts. Resistance to select BBI in GIST was attributable to drug efflux pumps. These results define a therapeutic vulnerability and clinical strategy for targeting oncogenic kinase dependency in GIST. SIGNIFICANCE: Expression and activity of mutant KIT is essential for driving the majority of GIST neoplasms, which can be therapeutically targeted using BET bromodomain inhibitors.
Collapse
Affiliation(s)
- Matthew L Hemming
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. .,Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
| | - Matthew A Lawlor
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Jessica L Andersen
- Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
| | - Timothy Hagan
- Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
| | - Otari Chipashvili
- Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
| | - Thomas G Scott
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Chandrajit P Raut
- Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Ewa Sicinska
- Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
| | - Scott A Armstrong
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
| | - George D Demetri
- Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.,Ludwig Center at Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts
| | - James E Bradner
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Congard A, Christophe V, Duprez C, Baudry AS, Antoine P, Lesur A, Loustalot C, Guillemet C, Leclercq M, Segura C, Carlier D, Lefeuvre-Plesse C, Simon H, Frenel JS, Vanlemmens L. The self-reported perceptions of the repercussions of the disease and its treatments on daily life for young women with breast cancer and their partners. J Psychosoc Oncol 2018; 37:50-68. [PMID: 30295567 DOI: 10.1080/07347332.2018.1479326] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
PURPOSE This study aimed to compare the self-reported perceptions of the repercussions of the disease and its treatments and emotional distress in young women with breast cancer and their partners. DESIGN Cross-sectional study using self-reported questionnaires. SAMPLE 491 couples in which women were aged <45 years when diagnosed with non-metastatic breast cancer in four different groups of treatment: during chemotherapy with or without Trastuzumab; under Trastuzumab with or without hormone therapy; during hormone therapy; and during the follow-up period. METHODS Patients and partners completed a questionnaire assessing their self-reported perceptions of the disease and treatments (Patient YW-BCI and Partner YW-BCI for the partners) and their emotional distress (CESD; STAI). FINDINGS Patients reported more difficulties than partners in the management of child(ren) and everyday life, body image and sexuality, negative affectivity about the disease and apprehension about the future, career management, and finances. While the difficulties were generally more marked in the chemotherapy and Trastuzumab groups than in the hormone therapy and follow-up groups, the negative affectivity about the disease and apprehension about the future was high in all four groups, especially in patients. The partners reported more difficulties in sharing with close relatives, and even more in those groups reflecting the latest treatment phases. No difference appeared between patients and partners in couple cohesion and deterioration of relationships with relatives. Partners were less anxious than patients but as depressed as them. CONCLUSIONS Difficulties of patients and partners seem particularly severe in the early care pathway, maybe reflecting better adjustment in women under surveillance and their partners. A longitudinal study will substantiate this finding and enable a better identification of some explanatory processes of these differences and similarities in the daily self-reported repercussions of the disease throughout the cancer care pathway. Implications for psychosocial oncology: It seems important to support young women with breast cancer and their partners, as our results evidence distress in both and differences according to the type of treatment the woman is currently receiving. Healthcare providers need consistent methods to identify and respond to couples' distress and reduce significant disparities in support.
Collapse
Affiliation(s)
- Anne Congard
- a Aix-Marseille Université , Centre de Recherche PsyCLE (EA 3273) , Aix en Provence , France
| | - Véronique Christophe
- b Univ. Lille, UMR 9193 - SCALab - Sciences Cognitives et Sciences Affectives , Lille , France.,c SIRIC ONCOLille , Lille , France
| | - Christelle Duprez
- b Univ. Lille, UMR 9193 - SCALab - Sciences Cognitives et Sciences Affectives , Lille , France.,c SIRIC ONCOLille , Lille , France
| | - Anne-Sophie Baudry
- b Univ. Lille, UMR 9193 - SCALab - Sciences Cognitives et Sciences Affectives , Lille , France.,c SIRIC ONCOLille , Lille , France
| | - Pascal Antoine
- b Univ. Lille, UMR 9193 - SCALab - Sciences Cognitives et Sciences Affectives , Lille , France
| | - Anne Lesur
- d Centre Alexis Vautrin , Vandoeuvre-les-Nancy , France
| | | | | | | | | | | | | | - Helene Simon
- k CHRU Brest Morvan Institut de cancérologie et hématologie , Brest , France
| | - Jean-Sebastien Frenel
- l Centre René Gauducheau , Institut de Cancérologie de l'Ouest , Saint-Herblain , France
| | | |
Collapse
|
10
|
Eliade M, Skrzypski J, Baurand A, Jacquot C, Bertolone G, Loustalot C, Coutant C, Guy F, Fumoleau P, Duffourd Y, Arnould L, Delignette A, Padéano MM, Lepage C, Raichon-Patru G, Boudrant A, Bône-Lépinoy MC, Villing AL, Charpin A, Peignaux K, Chevrier S, Vegran F, Ghiringhelli F, Boidot R, Sevenet N, Lizard S, Faivre L. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families? Oncotarget 2018; 8:1957-1971. [PMID: 27779110 PMCID: PMC5356770 DOI: 10.18632/oncotarget.12699] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2016] [Accepted: 08/13/2016] [Indexed: 12/30/2022] Open
Abstract
Until recently, the molecular diagnosis of hereditary breast and ovarian cancer (HBOC) was mostly based on BRCA1/2 testing. Next generation sequencing and the recent discovery of new genes involved in HBOC now permit the transfer of genomic capture targeting multiple candidate genes from research to clinical use. However, the implications for the management of patients and their families have not been extensively studied, in particular since some of these genes are not well-established cancer predisposing genes. We studied 583 consecutive patients from Burgundy (France) fulfilling the criteria for BRCA testing using a next generation sequencing 25-genes panel including 20 well-established high-risk cancer genes as well as more recently identified predisposing HBOC cancer. A pathogenic BRCA1/2 mutation was found in 51 patients (9%). Besides, we found 37 pathogenic or likely pathogenic mutations in 10 different high to low-risk genes in 34 patients (6%). The most frequently mutated genes were CHEK2 (n = 12; 2%), ATM (n = 9; 1.5%), and PALB2 (n = 4; 0.6%). Three patients had a mutation in two different predisposing genes. The analysis of clinical actionability conducted in mutation-positive individuals revealed that additional disease-specific screening and/or prevention measures beyond those based on personal and family history alone had been recommended in 69% of cases. In conclusion, multigene panel testing is a powerful tool to identifying high to low-risk HBOC susceptibility genes. The penetrance and spectrum of cancers with these other genes are sometimes undefined, and further collaborative work is crucial to address this question.
Collapse
Affiliation(s)
- Marie Eliade
- Centre of Genetic, Children Hospital, CHU, Dijon, France
| | - Jeremy Skrzypski
- Oncogenetic Unit, Centre Georges-François Leclerc Centre, Dijon, France
| | - Amandine Baurand
- Centre of Genetic, Children Hospital, CHU, Dijon, France.,Oncogenetic Unit, Centre Georges-François Leclerc Centre, Dijon, France
| | - Caroline Jacquot
- Centre of Genetic, Children Hospital, CHU, Dijon, France.,Oncogenetic Unit, Centre Georges-François Leclerc Centre, Dijon, France
| | - Geoffrey Bertolone
- Centre of Genetic, Children Hospital, CHU, Dijon, France.,Oncogenetic Unit, Centre Georges-François Leclerc Centre, Dijon, France
| | | | - Charles Coutant
- Gynecological Surgery, Georges-François Leclerc Centre, Dijon, France.,Burgundy Franche-Comté University, Dijon, France
| | - France Guy
- Radiology Unit, Georges-François Leclerc Centre, Dijon, France
| | - Pierre Fumoleau
- Medical Oncology, Georges-François Leclerc Centre, Dijon, France.,Burgundy Franche-Comté University, Dijon, France
| | | | - Laurent Arnould
- Biology and Tumor Pathology Department, Georges-François Leclerc Centre, Dijon, France
| | | | | | - Côme Lepage
- Hepato-Gastroenterology and Digestive Oncology, François Mitterand Hospital, CHU, Dijon, France.,Burgundy Franche-Comté University, INSERM LNC UMR866, Dijon, France
| | | | | | | | | | | | - Karine Peignaux
- Radiotherapy Unit, Georges-François Leclerc Centre, Dijon, France
| | - Sandy Chevrier
- Platform of Transfer in Cancer Biology, Georges-François Leclerc Centre, Dijon, France
| | - Frédérique Vegran
- Platform of Transfer in Cancer Biology, Georges-François Leclerc Centre, Dijon, France
| | - François Ghiringhelli
- Medical Oncology, Georges-François Leclerc Centre, Dijon, France.,Platform of Transfer in Cancer Biology, Georges-François Leclerc Centre, Dijon, France
| | - Romain Boidot
- Platform of Transfer in Cancer Biology, Georges-François Leclerc Centre, Dijon, France
| | | | - Sarab Lizard
- Biology and Tumor Pathology Department, Georges-François Leclerc Centre, Dijon, France
| | - Laurence Faivre
- Centre of Genetic, Children Hospital, CHU, Dijon, France.,Oncogenetic Unit, Centre Georges-François Leclerc Centre, Dijon, France
| |
Collapse
|
11
|
Grienay N, Henaff M, Sagot P, Gompel A, Coutant C, Loustalot C, De Maistre E, Delay E, Costedoat-Chalumeau N, Eric M, Mausservey C, Vinit J. Gigantomastie : un lien étroit avec l’auto-immunité ? Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Duprez C, Vanlemmens L, Untas A, Antoine P, Lesur A, Loustalot C, Guillemet C, Leclercq M, Segura C, Carlier D, Lefeuvre-Plesse C, Simon H, Frenel JS, Christophe V. Emotional distress and subjective impact of the disease in young women with breast cancer and their spouses. Future Oncol 2017; 13:2667-2680. [PMID: 29191056 DOI: 10.2217/fon-2017-0264] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
AIM Evaluate the influence of emotional distress of young women with breast cancer and their spouses on their daily subjective experience of the disease, through application of the Actor-Partner Interdependence Model. PATIENTS & METHODS A total of 112 women under 45 years of age were diagnosed with nonmetastatic breast cancer and their spouses answered self-reported measures of anxiety, depression and subjective experience of the disease and its treatment. RESULTS The patient's emotional distress influenced more the subjective experience of her spouse than the spouse's emotional distress influenced the patient. The spouse's difficulties depended as much on his own distress level as on the patient's distress level. CONCLUSION These data confirm the importance of implementing couple-focused interventions.
Collapse
Affiliation(s)
- Christelle Duprez
- Univ. Lille, CNRS, UMR 9193 - SCALab - Sciences Cognitives et Sciences Affectives, F-59000 Lille, France.,SIRIC ONCOLille - Maison Régionale de la Recherche Clinique - 6, rue du Professeur Laguesse, 59037 Lille cedex, France
| | - Laurence Vanlemmens
- Centre Oscar Lambret - Département de Sénologie, BP 307, F-59020 Lille cedex, France
| | - Aurélie Untas
- Laboratoire de Psychopathologie et Processus de Santé EA 4057, Institut de Psychologie, Université Paris Descartes, Sorbonne Paris Cité, Boulogne-Billancourt, France
| | - Pascal Antoine
- Univ. Lille, CNRS, UMR 9193 - SCALab - Sciences Cognitives et Sciences Affectives, F-59000 Lille, France
| | - Anne Lesur
- Centre Alexis Vautrin, 6 avenue de Bourgogne 59000 Vandœuvre-lès-Nancy, France
| | - Catherine Loustalot
- Centre Georges François Leclerc, 1 rue du Pr Marion BP 1544 21034 Dijon cedex, France
| | | | - Monelle Leclercq
- Collèges des gynécologues, 39 Boulevard Clémenceau 59700 Marcq-en-Barœul, France
| | - Carine Segura
- Centre François Baclesse, Avenue du Général Harris 14076 Caen Cedex 5, France
| | - Damien Carlier
- Centre Léonard de Vinci, route de Cambrai 59187 Dechy, France
| | - Claudia Lefeuvre-Plesse
- Centre Eugene Marquis, avenue de la Bataille Flandres-Dunkerque CS 44229 35042 Rennes Cedex, France
| | - Hélène Simon
- CHRU Brest Morvan Institut de cancérologie et hématologie, 5 avenue Foch 29200 Brest, France
| | - Jean Sébastien Frenel
- Institut de Cancérologie de l'Ouest, Centre René Gauducheau, ld Jacques Monod 44800 Saint-Herblain, France
| | - Véronique Christophe
- Univ. Lille, CNRS, UMR 9193 - SCALab - Sciences Cognitives et Sciences Affectives, F-59000 Lille, France.,SIRIC ONCOLille - Maison Régionale de la Recherche Clinique - 6, rue du Professeur Laguesse, 59037 Lille cedex, France
| |
Collapse
|
13
|
Vanlemmens L, Congard A, Duprez C, Baudry AS, Lesur A, Loustalot C, Guillemet C, Leclercq M, Levy C, Carlier D, Lefeuvre-Plesse C, Simon H, Frenel JS, Antoine P, Christophe V. Concerns of young women with breast cancer and theirs partners from chemotherapy to follow-up: a cross-sectional study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw390.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Lizard S, Eliade M, Skrzypski J, Baurand A, Jacquot C, Bertolone G, Loustalot C, Coutant C, Guy F, Fumoleau P, Duffourd Y, Arnould L, Padeano MM, Lepage C, Chevrier S, Végran F, Sevenet N, Ghiringhelli F, Boidot R, Faivre L. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families? J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e13116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | | | - Catherine Loustalot
- Department of Surgery/Georges François Leclerc Comprehensive Cancer Care Centre, Dijon, France
| | - Charles Coutant
- Department of Surgery/Georges François Leclerc Comprehensive Cancer Care Centre, Dijon, France
| | - France Guy
- Centre Georges François Leclerc, Dijon, France
| | | | | | - Laurent Arnould
- Department of Pathology, Centre Georges-Francois Leclerc, Dijon, France
| | | | - Come Lepage
- CHU Le Bocage HGE, INSERM U866, Dijon, France
| | | | - Frédérique Végran
- Biologie Et Pathologie Des Tumeurs, Centre Georges-François Leclerc, Dijon, France
| | | | | | - Romain Boidot
- Georges François Leclerc Cancer Center, Dijon, France
| | - Laurence Faivre
- Centre Hospitalier Universitaire Service de Génétique, Dijon, France
| |
Collapse
|
15
|
Molly D, Bertaut A, Blanchet C, Beltjens F, Charon-Barra C, Loustalot C, Desmoulins I, Arnould L. Abstract P1-01-14: Do estrogen receptor negative and progesterone receptor positive breast tumors really exist? Attitude for not making them real. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-01-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast tumors with negative estrogen receptor (ER-) and positive progesterone receptor (PR+) are rare (from 0 to 3.4 % according to the studies), and their existence is contested. These markers determine cancer molecular subtypes which play a determinant role for both the management and the prognosis of breast cancers. It is then essential to document the real existence of ER-/PR+ tumors. The present study aimed at determining if ER-/PR+ tumors share more basal or luminal characteristics.
Methods: Between 2000 and 2015, 50 patients with ER-/PR+ breast tumors, representing 0.6 % of all breast cancers diagnosed in our institution, were included in this study. Their clinical (age, node status), morphological (size, histological type, Elston and Ellis (EE) grade, necrosis, inflammation, pushing margins, central scar, mitotic index) and immunohistochemical characteristics (ER, PR, HER2, CK5/6 and EGFR status) were compared with those of 50 luminal and 50 triple negative (TN) tumors randomly selected in our lab database. At the time this abstract is written, the Ki67 index determination is still in progress. Five of these ER-/PR+ tumors were also given a molecular test (Nanostring). Qualitative variables were compared using Chi2 or Fisher test, quantitative variables were compared using Student or Mann & Whitney tests. To take into account for multiple comparisons, p-values less than 0.025 were considered as significant.
Results: The results are summarized in table 1. For almost all the analyzed criteria, ER-/PR+ tumors present statistical difference with luminal ones. On the contrary, they share most of TN tumors characteristics. The 5 molecular analyzes performed on ER-/PR+ samples showed the following phenotypes: 3 basal, 1 HER2 enriched and 1 luminal. For this last one, new immunohistological analyzes reveal in fact an ER+ staining.
Table 1: Study results ER-/PR+ tumorsER+ tumorsTN tumorsp ER-/PR+ vs ER+p ER-/PR+ vs TNSize (mm)23.12525.20.00440.4822Histological type0.00120.2424 ductal9480.4100 lobular219.60 neuro-endocrine40 Differentiation<10-40.4497 well09.80 moderately12.548.818 poorly87.541.582 EE grade<10-40.1016 14.135.34 236.74918 359.215.778 EE differentiation<10-40.3197 105.90 214.341.222 385.752.978 EE nuclear atypia<10-40.2227 102 234.774.522 365.325.576 EE mitosis<10-40.0123 124.580.418 230.613.710 344.95.972 Mitotic index (mitoses/mm2)9.52.210.2<10-40.1252Necrosis465.952<10-40.5484Inflammation0.00030.0011 yes30224 no4474.516 weak2623.560 CK5/6 +78.74.280.4<10-40.8378EGFR +44.74.252.2<10-40.4697HER2 +29.87.800.0051<10-4Results are given in %, excepting mitotic index and size
Conclusion: This study tends to support that ER-/PR+ tumors may not exist and are likely to be TN cancers or less frequently false negative ER+ tumors. In a practical point of view, we think that 1) when a tumor shows ER-/PR+ and TN characteristics, it is probably a false positive PR staining, and the tumor has to be considered as a TN one, 2) when an ER-/PR+ tumor don't fit the triple negative tumors characteristics, ER must be retested in order to exclude a true luminal tumor.
Citation Format: Molly D, Bertaut A, Blanchet C, Beltjens F, Charon-Barra C, Loustalot C, Desmoulins I, Arnould L. Do estrogen receptor negative and progesterone receptor positive breast tumors really exist? Attitude for not making them real. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-01-14.
Collapse
Affiliation(s)
- D Molly
- GF Leclerc Cancer Center, Dijon, France
| | - A Bertaut
- GF Leclerc Cancer Center, Dijon, France
| | | | | | | | | | | | - L Arnould
- GF Leclerc Cancer Center, Dijon, France
| |
Collapse
|
16
|
Vanlemmens L, Ploquin A, Delaloge S, Rouzier R, Lesur A, Frenel JS, Loustalot C, Bachelot T, Provansal M, Ferrero JM, Coussy F, Debled M, Kerbrat P, Vinceneux A, Djelila A, Baron M, Jebert S, Decoupigny E, Tresch E, Bonneterre J. Abstract P1-07-02: 5-year overall survival of early breast cancer during pregnancy: A multicenter French case control study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-07-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer (BC) during pregnancy (BCP) is a rare situation that requires collaboration between oncologists, surgeons and obstetricians. The main objectives of this study were to compare the overall survival (OS) and disease free survival (DFS) of a multicenter cohort of pregnant patients (pts) with those of matched control pts.
Methods: Patients from 27 centers and diagnosed between 2000 and 2006 with histological confirmed M0 invasive BC were included in this retrospective study. For the cohort of BCP, pts whose pregnancy was interrupted were not eligible. Controls were matched to BCP pts on 5 criteria: clinical T (of TNM), hormonal receptor (HR) status, HER2 status, administration of neo-adjuvant chemotherapy and pathological nodal status in the absence of neo-adjuvant chemotherapy. Survival times were estimated from the date of diagnosis using Kaplan-Meier method. OS was calculated until death from every cause, DFS was calculated until relapse or death from every cause; patients alive were censored at the date of last news.
Results: 100 BCP pts were identified. Their clinical and pathological characteristics were described on a previous presentation (SABCS 2013 P6-06-07). Matched controls could not be found for 12 BCP pts. 88 BCP pts were matched with 204 controls. The only differences between the 2 populations in terms of characteristics or treatment were more radical mastectomy (p=0.036) and fewer taxane administrations in the BCP group (p=0.06). The median duration of follow-up was 8.2 years for cases and 7.7 years for controls. There were no differences between BCP pts and controls in 5-year OS: 83.4%, IC 95% (73.5-89.8) vs 83.8%, IC 95% (77.9-88.3) nor 7-year OS: 76.5% (65.5-84.4) vs 78.1% (71.5-83.3) (p=0.52). The 5-year DFS was 58.6% IC 95% (47.3-68.3) vs 67.2% IC 95% (60.2-73.2) (p= 0.16). However, 5-year DFS was lower in HR+ BCP pts subgroup than in HR+ control group (56.7% IC 95% (40.7-69.8) vs 70.9% IC 95% (61.4-78.5) (p=0.023).
Conclusion: This multicenter French large study confirmed that there are no differences on OS and DFS between pregnant and no pregnant pts, though this might not be true for HR subgroup.
Citation Format: Vanlemmens L, Ploquin A, Delaloge S, Rouzier R, Lesur A, Frenel J-S, Loustalot C, Bachelot T, Provansal M, Ferrero J-M, Coussy F, Debled M, Kerbrat P, Vinceneux A, Djelila A, Baron M, Jebert S, Decoupigny E, Tresch E, Bonneterre J. 5-year overall survival of early breast cancer during pregnancy: A multicenter French case control study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-07-02.
Collapse
Affiliation(s)
- L Vanlemmens
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - A Ploquin
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - S Delaloge
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - R Rouzier
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - A Lesur
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - J-S Frenel
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - C Loustalot
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - T Bachelot
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - M Provansal
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - J-M Ferrero
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - F Coussy
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - M Debled
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - P Kerbrat
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - A Vinceneux
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - A Djelila
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - M Baron
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - S Jebert
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - E Decoupigny
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - E Tresch
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - J Bonneterre
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| |
Collapse
|
17
|
Burnier P, Hudry D, See LA, Duvernay A, Roche M, Loustalot C, Zwetyenga N, Coutant C. Patient age and breast resection weight affect immediate postmastectomy breast reconstruction in ductal carcinoma in situ. J Plast Reconstr Aesthet Surg 2015; 69:37-41. [PMID: 26576701 DOI: 10.1016/j.bjps.2015.09.023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2015] [Revised: 05/02/2015] [Accepted: 09/27/2015] [Indexed: 11/19/2022]
Abstract
PURPOSE Mastectomy is necessary for 40% of the ductal carcinoma in situ. If immediate breast reconstruction (IBR) is systematically proposed, 81% of the patients would choose immediate versus delayed breast reconstruction, but the actual IBR rate is only approximately 50% of them. Therefore, the aim of this study was to identify objective characteristics that distinguish the patients who actually underwent IBR from those who did not. METHODS Several criteria of 248 patients who have undergone mastectomy for ductal carcinoma were analyzed. Factors studied were age, body mass index, diabetes, tobacco use, and weight of the specimen of resection. RESULTS The rate of IBR was 43%. An increase in age and weight of the resection specimen, irrespective of the body mass index, was associated with a lower rate of IBR. Thus, an increase of 100 g in the weight of the breast induces a significant reduction of the IBR (33%). CONCLUSIONS In our series, older patients or patients with larger breasts (irrespective of the body mass index) were less likely to undergo IBR. In order to be in line with the patient's desire, the surgeons of our unit should broaden their indications of IBR. The lack of reconstruction of large breasts should certainly be compensated in part with the recent development of free tissue transfers in our unit. LEVEL OF EVIDENCE 3.
Collapse
Affiliation(s)
- Pierre Burnier
- Department of Plastic, Reconstructive and Aesthetic Surgery, 14 Rue Paul Gaffarel, Dijon, Côte d'Or, France; Department of Oncologic Surgery, Georges-François Leclerc Cancer Institute, 1 Rue du Professeur Marion, Dijon, Côte d'Or, France.
| | - Delphine Hudry
- Department of Oncologic Surgery, Georges-François Leclerc Cancer Institute, 1 Rue du Professeur Marion, Dijon, Côte d'Or, France; Dijon Univeristy, 7 Boulevard Jeanne d'Arc, Dijon, Côte d'Or, France
| | - Leslie-Ann See
- Department of Plastic, Reconstructive and Aesthetic Surgery, 14 Rue Paul Gaffarel, Dijon, Côte d'Or, France; Department of Oncologic Surgery, Georges-François Leclerc Cancer Institute, 1 Rue du Professeur Marion, Dijon, Côte d'Or, France; Dijon Univeristy, 7 Boulevard Jeanne d'Arc, Dijon, Côte d'Or, France
| | - Alain Duvernay
- Department of Oncologic Surgery, Georges-François Leclerc Cancer Institute, 1 Rue du Professeur Marion, Dijon, Côte d'Or, France
| | - Matthieu Roche
- Department of Oncologic Surgery, Georges-François Leclerc Cancer Institute, 1 Rue du Professeur Marion, Dijon, Côte d'Or, France
| | - Catherine Loustalot
- Department of Oncologic Surgery, Georges-François Leclerc Cancer Institute, 1 Rue du Professeur Marion, Dijon, Côte d'Or, France
| | - Narcisse Zwetyenga
- Department of Plastic, Reconstructive and Aesthetic Surgery, 14 Rue Paul Gaffarel, Dijon, Côte d'Or, France; Dijon Univeristy, 7 Boulevard Jeanne d'Arc, Dijon, Côte d'Or, France
| | - Charles Coutant
- Department of Oncologic Surgery, Georges-François Leclerc Cancer Institute, 1 Rue du Professeur Marion, Dijon, Côte d'Or, France; Dijon Univeristy, 7 Boulevard Jeanne d'Arc, Dijon, Côte d'Or, France
| |
Collapse
|
18
|
Beltjens F, Bertaut A, Pigeonnat S, Loustalot C, Desmoulins I, Charon-Barra C, Coudert B, Fumoleau P, Arveux P, Arnould L. HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable. Eur J Cancer Care (Engl) 2015; 26. [DOI: 10.1111/ecc.12404] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/20/2015] [Indexed: 12/18/2022]
Affiliation(s)
- F. Beltjens
- Department of Pathology; Centre GF Leclerc; Dijon France
| | - A. Bertaut
- Biostatistics and Epidemiology Unit; Centre GF Leclerc; Dijon France
| | - S. Pigeonnat
- Department of Pathology; Centre GF Leclerc; Dijon France
| | - C. Loustalot
- Department of Surgery; Centre GF Leclerc; Dijon France
| | - I. Desmoulins
- Department of Medical Oncology; Centre GF Leclerc; Dijon France
| | | | - B. Coudert
- Department of Medical Oncology; Centre GF Leclerc; Dijon France
| | - P. Fumoleau
- Department of Medical Oncology; Centre GF Leclerc; Dijon France
| | - P. Arveux
- Côte d'Or Breast Cancer Registry; Centre GF Leclerc; Dijon France
| | - L. Arnould
- Department of Pathology; Centre GF Leclerc; Dijon France
| |
Collapse
|
19
|
Vanlemmens L, Duprez C, Lesur A, Kaci FA, Congard A, Antoine P, Loustalot C, Guillemet C, Leclercq M, Levy C, Christophe V. Concerns About Sexuality of Young Women with Breast Cancer and Their Partners. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu352.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Vanlemmens L, Christophe V, Duprez C, Congard A, Lesur A, Loustalot C, Guillemet C, Leclercq M, Antoine P. The subjective quality of life of young patients with breast cancer and their partners. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.9569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Veronique Christophe
- University Lille Nord de France - Université de Lille 3, Villeneuve d'Ascq, France
| | | | | | - Anne Lesur
- Institut de Cancérologie de Lorraine, Vandœuvre-les- Nancy, France
| | - Catherine Loustalot
- Department of Surgery/Georges François Leclerc Comprehensive Cancer Care Centre, Dijon, France
| | | | | | | |
Collapse
|
21
|
Vanlemmens L, Delaloge S, Ploquin A, Bachelot T, Frenel JS, Loustalot C, Kerbrat P, Mignot L, Debled M, Allouache D, Vinceneux-Confavreux A, Provansal M, Dalenc F, Mouret-Reynier MA, Lerebours F, Jacot W, Tartas S, Morvan F, Jebert S, Decoupigny E, Rouzier R. Abstract P6-06-07: 5-year disease free-survival results of aggressively-treated breast cancer during pregnancy: Results from a French multicenter study. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-06-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer (BC) during pregnancy (BCP) is a rare situation that requires multi-disciplinary management. The objectives of this study were to assess the tumor characteristics, clinical course and outcome of such patients (pts).
Methods: French hospitals were invited to collect retrospective clinical, treatment and follow-up data of BCP managed between 2000 and 2006. Pts with histologically confirmed M0, invasive BC and pregnant at diagnosis were included. Pts whose pregnancy was interrupted were not eligible. Survival times were calculated from the date of diagnosis.
Results: 100 BCP pts were identified. Median age was 32 years (24-42). Median gestational age at diagnosis was 25 weeks (3-38). 84% and 13% had palpable breast axillary mass respectively. Clinical stages were 1T0, 21T1, 39T2, 28T3, 6 T4A-C, 2 T4D, 3 TX, 56 N0, 39 N1, 5 NX. Histological analysis identified 85 ductal carcinomas, 4 lobular, 11 others. The histopathological grades was G1 in 4,3%, G2 in 29%, and G3 in 66,7%. Tumor subtype was luminal A in 3%, luminal B in 37% (24HER2-, 13HER2+), luminal undetermined in 6%, triple-negative in 45,9%, Her2 + in 21,3%, and not classified in 2% (HR -, HER 2 unknown). Median time interval between first observation and biopsy was 31 days (0-337), respectively 40 days (0-337) and 15 days (0-172) when the first observation was made by patients or physicians. Median time interval between pathologic diagnosis and treatment was 18 days (0-295). Treatment was initiated after pregnancy for 42 pts, with median time of 18 days after delivery. 97 pts received chemotherapy with a median number of 6 cycles (4-11), 92 with anthracyclin, 44 with taxanes. 53 chemotherapy were administered in neo adjuvant setting among which 25 during pregnancy), and 44 in adjuvant setting (23 during pregnancy). 98 pts underwent surgery (34 during pregnancy), with 57 conservations and 41 mastectomies, 93 pts received radiotherapy and 43 hormone therapy after pregnancy. 10 pts received Trastuzumab. The mean gestational age at delivery was 35 weeks (22-45). All children were alive, with a median weight of 2735 g at birth (550-3740). The 5-year Overall Survival rate is 83% (95%CI 74-89), while Disease Free Survival is 53% (95%CI 43-63). First recurrence site was metastasis in 28, locoregional in 13, controlateral in 9 and other cancers in 2.
Conclusion: Biopsy and treatment intervals remain long among this population. In this large series BCP, there is an excess of triple-negative breast cancer. The 5-year OS rate is higher than previously reported but with DFS is lower. BCP remains an aggressive entity despite adapted treatment. Multivariate analysis will be presented. A comparison of this BCP population to matched controls is ongoing.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-06-07.
Collapse
Affiliation(s)
- L Vanlemmens
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - S Delaloge
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - A Ploquin
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - T Bachelot
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - J-S Frenel
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - C Loustalot
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - P Kerbrat
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - L Mignot
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - M Debled
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - D Allouache
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - A Vinceneux-Confavreux
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - M Provansal
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - F Dalenc
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - M-A Mouret-Reynier
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - F Lerebours
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - W Jacot
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - S Tartas
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - F Morvan
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - S Jebert
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - E Decoupigny
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - R Rouzier
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| |
Collapse
|
22
|
Degrolard-Courcet E, Sokolowska J, Padeano MM, Guiu S, Bronner M, Chery C, Coron F, Lepage C, Chapusot C, Loustalot C, Jouve JL, Hatem C, Ferrant E, Martin L, Coutant C, Baurand A, Couillault G, Delignette A, El Chehadeh S, Lizard S, Arnould L, Fumoleau P, Callier P, Mugneret F, Philippe C, Frebourg T, Jonveaux P, Faivre L. Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene. Eur J Hum Genet 2013; 22:979-87. [PMID: 24301060 DOI: 10.1038/ejhg.2013.278] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2013] [Revised: 10/02/2013] [Accepted: 10/10/2013] [Indexed: 12/30/2022] Open
Abstract
Fanconi anaemia (FA) is characterized by progressive bone marrow failure, congenital anomalies, and predisposition to malignancy. In a minority of cases, FA results from biallelic FANCD1/BRCA2 mutations that are associated with early-onset leukaemia and solid tumours. Here, we describe the clinical and molecular features of a remarkable family presenting with multiple primary colorectal cancers (CRCs) without detectable mutations in genes involved in the Mendelian predisposition to CRCs. We unexpectedly identified, despite the absence of clinical cardinal features of FA, a biallelic mutation of the FANCD1/BRCA2 corresponding to a frameshift alteration (c.1845_1846delCT, p.Asn615Lysfs*6) and a missense mutation (c.7802A>G, p.Tyr2601Cys). The diagnosis of FA was confirmed by the chromosomal analysis of lymphocytes. Reverse transcriptase (RT)-PCR analysis revealed that the c.7802A>G BRCA2 variation was in fact a splicing mutation that creates an aberrant splicing donor site and results partly into an aberrant transcript encoding a truncated protein (p.Tyr2601Trpfs*46). The atypical FA phenotype observed within this family was probably explained by the residual amount of BRCA2 with the point mutation c.7802A>G in the patients harbouring the biallelic FANCD1/BRCA2 mutations. Although this report is based in a single family, it suggests that CRCs may be part of the tumour spectrum associated with FANCD1/BRCA2 biallelic mutations and that the presence of such mutations should be considered in families with CRCs, even in the absence of cardinal features of FA.
Collapse
Affiliation(s)
- Emilie Degrolard-Courcet
- Service d'Anatomie et Cytologie Pathologiques, Pole Technique et biologie CHU Dijon, Dijon, France
| | - Joanna Sokolowska
- Laboratoire de Génétique et INSERM U-954, CHU Nancy, Université de Lorraine, Nancy, France
| | - Marie-Martine Padeano
- Département de Chirurgie, Centre de lutte anti-cancereux Georges François Leclerc, Dijon, France
| | - Séverine Guiu
- Département d'oncologie médicale, Centre de lutte anti-cancereux Georges François Leclerc, Dijon, France
| | - Myriam Bronner
- Laboratoire de Génétique et INSERM U-954, CHU Nancy, Université de Lorraine, Nancy, France
| | - Carole Chery
- Laboratoire de Génétique et INSERM U-954, CHU Nancy, Université de Lorraine, Nancy, France
| | - Fanny Coron
- Centre de Génétique, Hôpital d'Enfants, CHU Dijon et Université de bourgogne, Dijon, France
| | - Côme Lepage
- Service d' Hepato-gastro-enterologie, CHU "Bocage Central", Dijon, France
| | - Caroline Chapusot
- Service d'Anatomie et Cytologie Pathologiques, Pole Technique et biologie CHU Dijon, Dijon, France
| | - Catherine Loustalot
- Département de Chirurgie, Centre de lutte anti-cancereux Georges François Leclerc, Dijon, France
| | - Jean-Louis Jouve
- Service d' Hepato-gastro-enterologie, CHU "Bocage Central", Dijon, France
| | - Cyril Hatem
- Hepato-gastro-entérologie, Clinique Drevon, Dijon, France
| | - Emmanuelle Ferrant
- Service d'Hématologie Clinique, Hôpital d'Enfants, CHU Dijon, Dijon, France
| | - Laurent Martin
- Service d'Anatomie et Cytologie Pathologiques, Pole Technique et biologie CHU Dijon, Dijon, France
| | - Charles Coutant
- Département de Chirurgie, Centre de lutte anti-cancereux Georges François Leclerc, Dijon, France
| | - Amandine Baurand
- Centre de Génétique, Hôpital d'Enfants, CHU Dijon et Université de bourgogne, Dijon, France
| | | | - Alexandra Delignette
- Service de Radiologie, Centre de lutte anti-cancereux Georges François Leclerc, Dijon, France
| | - Salima El Chehadeh
- Centre de Génétique, Hôpital d'Enfants, CHU Dijon et Université de bourgogne, Dijon, France
| | - Sarab Lizard
- Biologie Moléculaire, Centre de lutte anti-cancereux Georges François Leclerc, Dijon, France
| | - Laurent Arnould
- Anatomopathologie, Centre de lutte anti-cancereux Georges François Leclerc, Dijon, France
| | - Pierre Fumoleau
- Département d'oncologie médicale, Centre de lutte anti-cancereux Georges François Leclerc, Dijon, France
| | - Patrick Callier
- Service de Cytogénétique, Pole Technique et biologie, CHU Dijon, Dijon, France
| | - Francine Mugneret
- Service de Cytogénétique, Pole Technique et biologie, CHU Dijon, Dijon, France
| | - Christophe Philippe
- Laboratoire de Génétique et INSERM U-954, CHU Nancy, Université de Lorraine, Nancy, France
| | | | - Philippe Jonveaux
- Laboratoire de Génétique et INSERM U-954, CHU Nancy, Université de Lorraine, Nancy, France
| | - Laurence Faivre
- Centre de Génétique, Hôpital d'Enfants, CHU Dijon et Université de bourgogne, Dijon, France
| |
Collapse
|
23
|
Dabakuyo TS, De Gournay E, Guyomard A, Boulet S, Arveux P, Causeret S, Gouy S, Padeano MM, Loustalot C, Smail M, Sauzedde JM, Combier JP, Chevillote P, Rosburger C, Bonnetain F, Coutant C, Fraisse J. Long-term quality of life in patients with breast cancer according to sentinel lymph node biopsy or axillary lymph node dissection: A multicenter cohort study with 6 years follow-up. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.1114] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1114 Background: the aim of this study was to assess long term quality of life (QoL) over a period of 6 years in women with a breast cancer (BC) who underwent sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), or SLNB followed by ALND. Methods: The EORTC-QLQ-C30 and the EORTC-QLQ-BR-23 questionnaires were used to assess QoL before surgery, just after surgery, 6, 12 and 72 months later. The Kruskal Wallis test with the Bonferroni correction was used to compare scores. A mixed model analysis of variance for repeated measurements was then applied to assess the longitudinal effect of surgical modalities on QoL. Results: Five hundred and eighteen BC patients were initially included. The median follow-up was 6 years. During the follow-up, 61 patients died. None of the patients of the SLNB group has developed lymphedema during follow-up and the relapse rate was not different between the different groups (p=0.62). Before surgery, global health (GHS) (P = 0.5226) and arm symptoms (BRAS) (P = 0.9902) QoL scores were similar whatever the surgical procedure. BRAS score (p=0.0001) was better in the SNLB group 72 months after surgery. Moreover, compared to ALND patients, patients treated with SLNB had fewer arm symptoms with the follow-up. In addition, body image (P = 0.0005), upset by hair loss (P = 0.0045), systemic therapy side effects (P = 0.0097) and future perspective (P = 0.0375) QoL dimensions remained better 5 to 6 years after diagnosis in patients treated by SLNB. Conclusions: Long term follow-up showed that, SLNB is a safe and acceptable accurate method associated with less morbidity than ALND.
Collapse
Affiliation(s)
- Tienhan Sandrine Dabakuyo
- Biostatistics and Quality of Life Unit/Centre Georges François Leclerc and EA 4184, Faculty of Medicine, Dijon, France
| | - Emmanuel De Gournay
- Department of Surgery/Georges François Leclerc Comprehensive Cancer Care Centre, Dijon, France
| | - Aurelie Guyomard
- Department of Surgery/Georges François Leclerc Comprehensive Cancer Care Centre, Dijon, France
| | - Stephanie Boulet
- Department of Surgery/Georges François Leclerc Comprehensive Cancer Care Centre, Dijon, France
| | - Patrick Arveux
- Biostatistics and Quality of Life Unit/Centre Georges François Leclerc and EA 4184, Faculty of Medicine, Dijon, France
| | - Sylvain Causeret
- Department of Surgery/Georges François Leclerc Comprehensive Cancer Care Centre, Dijon, France
| | - Sebastien Gouy
- Department of Surgery/Georges François Leclerc Comprehensive Cancer Care Centre, Dijon, France
| | - Marie-Martine Padeano
- Department of Surgery/Georges François Leclerc Comprehensive Cancer Care Centre, Dijon, France
| | - Catherine Loustalot
- Department of Surgery/Georges François Leclerc Comprehensive Cancer Care Centre, Dijon, France
| | - Marc Smail
- Clinique Sainte Marie, Chalon sur Saone, France
| | | | | | | | | | - Franck Bonnetain
- Methodology and Quality of Life in Oncology Unit (EA 3181) & Quality of Life and Cancer Clinical Research Plateform, Besancon, France
| | - Charles Coutant
- Department of Surgery/Georges François Leclerc Comprehensive Cancer Care Centre, Dijon, France
| | - Jean Fraisse
- Department of Surgery/Georges François Leclerc Comprehensive Cancer Care Centre, Dijon, France
| |
Collapse
|
24
|
Delpech Y, Bricou A, Lousquy R, Hudry D, Jankowski C, Willecocq C, Thoury A, Loustalot C, Coutant C, Barranger E. The Exportability of the ACOSOG Z0011 Criteria for Omitting Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy Findings: A Multicenter Study. Ann Surg Oncol 2013; 20:2556-61. [DOI: 10.1245/s10434-013-2917-6] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2012] [Indexed: 11/18/2022]
|
25
|
Humbert O, Berriolo-Riedinger A, Riedinger JM, Coudert B, Arnould L, Cochet A, Loustalot C, Fumoleau P, Brunotte F. Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Ann Oncol 2012; 23:2572-2577. [PMID: 22499859 DOI: 10.1093/annonc/mds071] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND The aim of this study is to evaluate the impact of the different breast cancer subtypes on the tumor (18)F-FDG uptake at baseline and on its changes after the first course of neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS One hundred and fifteen women with newly diagnosed, large or locally advanced breast cancer undergoing NAC were included. Estrogen receptor (ER), progesterone receptor (PR) and HER2 status were used to define three major tumor subtypes: triple negative (TN) (ER-/PR-/HER2-), luminal (ER+ and/or PR+; HER2-) and HER2 positive (HER2+). Using Fluorine-18 fluorodeoxyglucose positron emission tomography, the tumoral standard uptake value (SUV) maximal index was measured at baseline and just before the second course of NAC. RESULTS TN tumors presented the highest baseline SUV (11.3 ± 8.5; P < 0.0001). The decrease of SUV after the first course of NAC (ΔSUV) was significantly higher in TN and HER2-positive subtypes (-45% ± 25% and -57% ± 30%, respectively) than in luminal one (-19% ± 35%; P < 0.0001). ΔSUV was a predictive factor of the pathological complete response only in HER2-positive tumors (cut-off = -75%; P < 0.03) with an accuracy of 76%. CONCLUSION The baseline (18)F-FDG tumoral uptake but also its early response to NAC is different according to the immunohistological subtypes of breast cancer.
Collapse
Affiliation(s)
- O Humbert
- Departments of Nuclear Medicine, Dijon, France.
| | | | | | - B Coudert
- Depertment of Medical Oncology, Dijon, France
| | | | - A Cochet
- Departments of Nuclear Medicine, Dijon, France; LE2I, UMR CNRS 5158, Université de Bourgogne, Dijon, France
| | | | - P Fumoleau
- Depertment of Medical Oncology, Dijon, France; LE2I, UMR CNRS 5158, Université de Bourgogne, Dijon, France
| | - F Brunotte
- Departments of Nuclear Medicine, Dijon, France; LE2I, UMR CNRS 5158, Université de Bourgogne, Dijon, France
| |
Collapse
|
26
|
Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Sinilnikova OM, Healey S, Barrowdale D, Lee A, Thomassen M, Gerdes AM, Kruse TA, Jensen UB, Skytte AB, Caligo MA, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Złowocka E, Gronwald J, Huzarski T, Byrski T, Cybulski C, Toloczko-Grabarek A, Osorio A, Benitez J, Duran M, Tejada MI, Hamann U, Rookus M, van Leeuwen FE, Aalfs CM, Meijers-Heijboer HE, van Asperen CJ, van Roozendaal K, Hoogerbrugge N, Collée JM, Kriege M, van der Luijt RB, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Jacobs C, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Paterson J, Douglas F, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Pathak H, Godwin AK, Stoppa-Lyonnet D, Caux-Moncoutier V, de Pauw A, Gauthier-Villars M, Mazoyer S, Léoné M, Calender A, Lasset C, Bonadona V, Hardouin A, Berthet P, Bignon YJ, Uhrhammer N, Faivre L, Loustalot C, Buys S, Daly M, Miron A, Terry MB, Chung WK, John EM, Southey M, Goldgar D, Singer CF, Tea MK, Pfeiler G, Fink-Retter A, Hansen TVO, Ejlertsen B, Johannsson OT, Offit K, Kirchhoff T, Gaudet MM, Vijai J, Robson M, Piedmonte M, Phillips KA, Van Le L, Hoffman JS, Toland AE, Montagna M, Tognazzo S, Imyanitov E, Isaacs C, Janavicius R, Lazaro C, Blanco I, Tornero E, Navarro M, Moysich KB, Karlan BY, Gross J, Olah E, Vaszko T, Teo SH, Ganz PA, Beattie MS, Dorfling CM, van Rensburg EJ, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Schäfer D, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Plante M, Spurdle AB, Neuhausen SL, Ding YC, Wang X, Lindor N, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Bonanni B, Bernard L, Dolcetti R, Papi L, Ottini L, Radice P, Greene MH, Mai PL, Andrulis IL, Glendon G, Ozcelik H, Pharoah PD, Gayther SA, Simard J, Easton DF, Couch FJ, Chenevix-Trench G. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat 2012; 33:690-702. [PMID: 22253144 PMCID: PMC3458423 DOI: 10.1002/humu.22025] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2011] [Accepted: 12/14/2011] [Indexed: 01/16/2023]
Abstract
Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Four single-nucleotide polymorphisms (SNPs), rs10088218 (at 8q24), rs2665390 (at 3q25), rs717852 (at 2q31), and rs9303542 (at 17q21), were genotyped in 12,599 BRCA1 and 7,132 BRCA2 carriers, including 2,678 ovarian cancer cases. Associations were evaluated within a retrospective cohort approach. All four loci were associated with ovarian cancer risk in BRCA2 carriers; rs10088218 per-allele hazard ratio (HR) = 0.81 (95% CI: 0.67-0.98) P-trend = 0.033, rs2665390 HR = 1.48 (95% CI: 1.21-1.83) P-trend = 1.8 × 10(-4), rs717852 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.6 × 10(-4), rs9303542 HR = 1.16 (95% CI: 1.02-1.33) P-trend = 0.026. Two loci were associated with ovarian cancer risk in BRCA1 carriers; rs10088218 per-allele HR = 0.89 (95% CI: 0.81-0.99) P-trend = 0.029, rs2665390 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.1 × 10(-4). The HR estimates for the remaining loci were consistent with odds ratio estimates for the general population. The identification of multiple loci modifying ovarian cancer risk may be useful for counseling women with BRCA1 and BRCA2 mutations regarding their risk of ovarian cancer.
Collapse
Affiliation(s)
- Susan J. Ramus
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, California
| | - Antonis C Antoniou
- Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - Karoline B. Kuchenbaecker
- Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - Penny Soucy
- Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Canada
| | - Jonathan Beesley
- Genetics and Population Health Division, Queensland Institute of Medical Research, Herston, Australia
| | - Xiaoqing Chen
- Genetics and Population Health Division, Queensland Institute of Medical Research, Herston, Australia
| | - Lesley McGuffog
- Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - Olga M. Sinilnikova
- Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre Hospitalier Universitaire de Lyon / Centre Léon Bérard, Lyon, France
- INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Sue Healey
- Genetics and Population Health Division, Queensland Institute of Medical Research, Herston, Australia
| | - Daniel Barrowdale
- Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - Andrew Lee
- Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - Mads Thomassen
- Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
| | - Anne-Marie Gerdes
- Department of Clincial Genetics, Rigshospital and Copenhagen University, Copenhagen, Denmark
| | - Torben A. Kruse
- Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
| | - Uffe Birk Jensen
- Department of Clinical Genetics, Skejby Hospital, Aarhus, Denmark
| | | | - Maria A. Caligo
- Section of Genetic Oncology, Department of Laboratory Medicine, University and University Hospital of Pisa, Pisa, Italy
| | - Annelie Liljegren
- Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
| | - Annika Lindblom
- Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden
| | - Håkan Olsson
- Department of Oncology, Lund University Hospital, Lund, Sweden
| | | | - Marie Stenmark-Askmalm
- Division of Clinical Genetics, Department of Clinical and Experimental Medicine, Linköping University, Linkoping, Sweden
| | - Beatrice Melin
- Department of Radiation Sciences, Oncology, Umeå University, Umea, Sweden
| | - SWE-BRCA
- Swedish Breast Cancer Study, Stockholm, Sweden
| | - Susan M. Domchek
- Abramson Cancer Center, and Perelman School of Medicine, Philadelphia, University of Pennsylvania
| | - Katherine L. Nathanson
- Abramson Cancer Center, and Perelman School of Medicine, Philadelphia, University of Pennsylvania
| | - Timothy R. Rebbeck
- Abramson Cancer Center, and Perelman School of Medicine, Philadelphia, University of Pennsylvania
| | - Anna Jakubowska
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Jan Lubinski
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Katarzyna Jaworska
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
- Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland
| | - Katarzyna Durda
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Elżbieta Złowocka
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Jacek Gronwald
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Tomasz Huzarski
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Tomasz Byrski
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Cezary Cybulski
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | | | - Ana Osorio
- Human Genetics Group, Spanish National Cancer Centre (CNIO), Madrid, Spain, and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain
| | - Javier Benitez
- Human Genetics Group, Spanish National Cancer Centre (CNIO), Madrid, Spain, and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain
| | - Mercedes Duran
- Institute of Biology and Molecular Genetics, University of Valladolid, Valladolid, Spain
| | | | - Ute Hamann
- Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
| | - Matti Rookus
- Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Flora E. van Leeuwen
- Department of Epidemiology, Division of Psychosocial Research & Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Cora M. Aalfs
- Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands
| | | | - Christi J. van Asperen
- Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | | | - Nicoline Hoogerbrugge
- Hereditary Cancer Clinic, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
| | - J. Margriet Collée
- Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Mieke Kriege
- Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Rob B. van der Luijt
- Department of Medical Genetics, University Medical Center Utrecht, The Netherlands
| | - HEBON
- Hereditary Breast Ovarian Cancer Group, Amsterdam, The Netherlands
| | - EMBRACE
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - Susan Peock
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - Debra Frost
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - Steve D. Ellis
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - Radka Platte
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - Elena Fineberg
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - D. Gareth Evans
- Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation, Manchester, United Kingdom
| | - Fiona Lalloo
- Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation, Manchester, United Kingdom
| | - Chris Jacobs
- Clinical Genetics, Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
| | - Ros Eeles
- Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Julian Adlard
- Yorkshire Regional Genetics Service, Leeds, United Kingdom
| | - Rosemarie Davidson
- Ferguson-Smith Centre for Clinical Genetics, Yorkhill Hospitals, Glasgow, United Kingdom
| | - Diana Eccles
- University of Southampton Faculty of Medicine, Southampton University Hospitals NHS Trust, Southampton, United Kingdom
| | - Trevor Cole
- West Midlands Regional Genetics Service, Birmingham Women’s Hospital Healthcare NHS Trust, Edgbaston, Birmingham, United Kingdom
| | - Jackie Cook
- Sheffield Clinical Genetics Service, Sheffield Children’s Hospital, Sheffield, United Kingdom
| | - Joan Paterson
- Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom
| | - Fiona Douglas
- Institute of Genetic Medicine, Centre for Life, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom
| | - Carole Brewer
- Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom
| | - Shirley Hodgson
- Medical Genetics Unit, St George’s, University of London, London, United Kingdom
| | - Patrick J. Morrison
- Northern Ireland Regional Genetics Centre, Belfast Health and Social Care Trust, and Department of Medical Genetics, Queens University Belfast, Belfast, United Kingdom
| | - Lisa Walker
- Oxford Regional Genetics Service, Churchill Hospital, Oxford, United Kingdom
| | - Mary E. Porteous
- South East of Scotland Regional Genetics Service, Western General Hospital, Edinburgh, United Kingdom
| | - M. John Kennedy
- Academic Unit of Clinical and Molecular Oncology, Trinity College Dublin and St James’s Hospital, Dublin, Ireland
| | - Harsh Pathak
- Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas
| | - Andrew K. Godwin
- Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas
| | - Dominique Stoppa-Lyonnet
- Service de Génétique Oncologique, Institut Curie, Paris, France
- Unité INSERM U830, Institut Curie, Paris, France
- Université Paris Descartes, Faculté de Médecine, Paris, France
| | | | - Antoine de Pauw
- Service de Génétique Oncologique, Institut Curie, Paris, France
| | | | - Sylvie Mazoyer
- INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | - Mélanie Léoné
- Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre Hospitalier Universitaire de Lyon / Centre Léon Bérard, Lyon, France
| | - Alain Calender
- Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre Hospitalier Universitaire de Lyon / Centre Léon Bérard, Lyon, France
| | - Christine Lasset
- Université Lyon 1, CNRS UMR5558, Lyon, France
- Unité de Prévention et d’Epidémiologie Génétique, Centre Léon Bérard, Lyon, France
| | - Valérie Bonadona
- Université Lyon 1, CNRS UMR5558, Lyon, France
- Unité de Prévention et d’Epidémiologie Génétique, Centre Léon Bérard, Lyon, France
| | | | | | - Yves-Jean Bignon
- Département d’Oncogénétique, Centre Jean Perrin, Université d’Auvergne, Auvergne, France
| | - Nancy Uhrhammer
- Département d’Oncogénétique, Centre Jean Perrin, Université d’Auvergne, Auvergne, France
| | - Laurence Faivre
- Centre de Génétique, CHU Dijon, Université de Bourgogne, Dijon, France
- Centre Georges François Leclerc, Dijon, France
| | | | - GEMO
- GEMO study: Cancer Genetics Network “Groupe Génétique et Cancer”, Fédération Nationale des Centres de Lutte Contre le Cancer, Paris, France
| | - Saundra Buys
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City
| | - Mary Daly
- Fox Chase Cancer Center, Philadelphia, Pennsylvania
| | - Alex Miron
- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Mary Beth Terry
- Department of Epidemiology, Columbia University, New York, NY
| | - Wendy K. Chung
- Department of Epidemiology, Columbia University, New York, NY
| | - Esther M John
- Department of Epidemiology, Cancer Prevention Institute of California, Fremont, California
| | - Melissa Southey
- Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Melbourne, Australia
| | - David Goldgar
- Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah
| | - Christian F Singer
- Department of OB/GYN and Comprehensive Cancer Center, Medical University of Austria, Vienna, Austria
| | - Muy-Kheng Tea
- Department of OB/GYN and Comprehensive Cancer Center, Medical University of Austria, Vienna, Austria
| | - Georg Pfeiler
- Department of OB/GYN and Comprehensive Cancer Center, Medical University of Austria, Vienna, Austria
| | - Anneliese Fink-Retter
- Department of OB/GYN and Comprehensive Cancer Center, Medical University of Austria, Vienna, Austria
| | - Thomas v. O. Hansen
- Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Bent Ejlertsen
- Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Oskar Th. Johannsson
- Department of Oncology, Landspitali University Hospital, Reykjavik, Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland
| | - Kenneth Offit
- Clinical Cancer Genetics Laboratory, Memorial Sloane Kettering Cancer Center, New York, NY
| | - Tomas Kirchhoff
- Department of Environmental Medicine, NYU Cancer Institute, New York University School of Medicine, New York, NY
| | - Mia M. Gaudet
- Epidemiology Research Program, American Cancer Society, Atlanta, Georgia
| | - Joseph Vijai
- Clinical Cancer Genetics Laboratory, Memorial Sloane Kettering Cancer Center, New York, NY
| | - Mark Robson
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Marion Piedmonte
- Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY
| | - Kelly-Anne Phillips
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia
| | - Linda Van Le
- Gynecologic Oncology Group, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | | | - Amanda Ewart Toland
- Divison of Human Cancer Genetics, Departments of Internal Medicine and Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
| | - Marco Montagna
- Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV - IRCCS, Padua, Italy
| | - Silvia Tognazzo
- Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV - IRCCS, Padua, Italy
| | - Evgeny Imyanitov
- Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, St.-Petersburg, Russia
| | - Claudine Isaacs
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC
| | - Ramunas Janavicius
- Vilnius University Hospital Santariskiu Clinics, Hematology, Oncology and Transfusion Medicine Center, Department of Molecular and Regenerative Medicine; State Research Institute Inovative Medicine Center, Vilnius, Lithuania
| | - Conxi Lazaro
- Molecular Diagnostic Unit, Hereditari Cancer Program, IDIBELL-Catalan Institute of Oncology, Catalanes, Spain
| | - Ignacio Blanco
- Genetic Counseling Unit, Hereditari Cancer Program, IDIBELL-Catalan Institute of Oncology, Catalanes, Spain
| | - Eva Tornero
- Molecular Diagnostic Unit, Hereditari Cancer Program, IDIBELL-Catalan Institute of Oncology, Catalanes, Spain
| | - Matilde Navarro
- Genetic Counseling Unit, Hereditari Cancer Program, IDIBELL-Catalan Institute of Oncology, Catalanes, Spain
| | - Kirsten B. Moysich
- Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York
| | - Beth Y. Karlan
- Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Jenny Gross
- Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Edith Olah
- Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary
| | - Tibor Vaszko
- Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary
| | - Soo-Hwang Teo
- Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Malaysia and University Malaya Cancer Research Institute, University Malaya, Kuala Lumpur, Malaysia
| | - Patricia A. Ganz
- UCLA Schools of Medicine and Public Health, Division of Cancer Prevention & Control Research, Jonsson Comprehensive Cancer Center, Los Angeles, California
| | - Mary S. Beattie
- University of California, San Francisco, Departments of Medicine, Epidemiology, and Biostatistics, San Francisco, California
| | - Cecelia M Dorfling
- Cancer Genetics Laboratory, Department of Genetics, University of Pretoria, Pretoria, South Africa
| | - Elizabeth J van Rensburg
- Cancer Genetics Laboratory, Department of Genetics, University of Pretoria, Pretoria, South Africa
| | - Orland Diez
- Oncogenetics Laboratory. Vall d’Hebron Institute of Oncology (VHIO); University Hospital Vall d’Hebron, Barcelona, Spain
| | - Ava Kwong
- The Hong Kong Hereditary Breast Cancer Family Registry; Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Hong Kong; Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong
| | - Rita K. Schmutzler
- Centre of Familial Breast and Ovarian Cancer, Department of Gynaecology and Obstetrics and Centre for Integrated Oncology (CIO), University Hospital of Cologne, Cologne, Germany
| | - Barbara Wappenschmidt
- Centre of Familial Breast and Ovarian Cancer, Department of Gynaecology and Obstetrics and Centre for Integrated Oncology (CIO), University Hospital of Cologne, Cologne, Germany
| | - Christoph Engel
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
| | - Alfons Meindl
- Department of Gynaecology and Obstetrics, Division of Tumor Genetics, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
| | - Nina Ditsch
- Department of Gynaecology and Obstetrics, Ludwig-Maximilian University Munich, Munich, Germany
| | - Norbert Arnold
- Department of Gynaecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany
| | - Simone Heidemann
- Institute of Human Genetics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany
| | - Dieter Niederacher
- Department of Gynaecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Dusseldorf, Germany
| | | | - Dorotehea Gadzicki
- Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany
| | | | - Helmut Deissler
- Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - Andrea Gehrig
- Centre of Familial Breast and Ovarian Cancer, Department of Medical Genetics, Institute of Human Genetics, University Würzburg, Wuzburg, Germany
| | - Christian Sutter
- Institute of Human Genetics, Department of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany
| | - Karin Kast
- Department of Gynaecology and Obstetrics, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
| | - Britta Fiebig
- Institute of Human Genetics, University Regensburg, Regensburg, Germany
| | - Dieter Schäfer
- Institute of Human Genetics, University Hospital Frankfurt a.M., Frankfurt, Germany
| | - Trinidad Caldes
- Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain
| | - Miguel de la Hoya
- Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain
| | - Heli Nevanlinna
- Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
| | - Kristiina Aittomäki
- Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland
| | - Marie Plante
- Gynaecologic Oncology Service, Centre Hospitalier Universitaire de Québec (CHUQ), Côte du Palais, Québec, Canada
| | - Amanda B. Spurdle
- Genetics and Population Health Division, Queensland Institute of Medical Research, Herston, Australia
| | - kConFab
- Kathleen Cuningham Consortium for Research into Familial Breast Cancer–Peter MacCallum Cancer Center, Melbourne, Australia
| | - Susan L. Neuhausen
- Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California
| | - Yuan Chun Ding
- Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California
| | - Xianshu Wang
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
| | - Noralane Lindor
- Department of Medical Genetics, Mayo Clinic, Rochester, Minnesota
| | | | - V. Shane Pankratz
- Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota
| | - Paolo Peterlongo
- Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predicted Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy
- IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy
| | - Siranoush Manoukian
- Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy
| | - Bernard Peissel
- Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy
| | - Daniela Zaffaroni
- Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy
| | - Bernardo Bonanni
- Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO), Milan, Italy
| | - Loris Bernard
- Department of Experimental Oncology, Istituto Europeo di Oncologia, Milan, Italy
- Consortium for Genomics Technology (Cogentech), Milan, Italy
| | - Riccardo Dolcetti
- Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, IRCCS, Aviano (PN), Italy
| | - Laura Papi
- Medical Genetics Unit, Department of Clinical Physiopathology, University of Florence, Firenze, Italy
| | - Laura Ottini
- Department of Molecular Medicine, “Sapienza” University of Rome, Rome, Italy
| | - Paolo Radice
- Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predicted Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy
- IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy
| | - Mark H. Greene
- Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland
| | - Phuong L. Mai
- Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland
| | - Irene L. Andrulis
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1×5, Cancer Care Ontario, Departments of Molecular Genetics and Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
| | - Gord Glendon
- Ontario Cancer Genetics Network: Cancer Care Ontario, Ontario, Canada
| | - Hilmi Ozcelik
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1×5, Cancer Care Ontario, Departments of Molecular Genetics and Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
| | - OCGN
- Ontario Cancer Genetics Network: Cancer Care Ontario, Ontario, Canada
| | - Paul D.P. Pharoah
- Department of Oncology, University of Cambridge, Cambridge, United Kingdom
| | - Simon A. Gayther
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, California
| | - Jacques Simard
- Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Canada
| | - Douglas F. Easton
- Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - Fergus J. Couch
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
| | - Georgia Chenevix-Trench
- Genetics and Population Health Division, Queensland Institute of Medical Research, Herston, Australia
| |
Collapse
|
27
|
Tunon-de-lara C, Giard S, Baron M, Le-Bouedec G, Garbay JR, Blanchot J, Mollard J, Charitansky H, Martin-Françoise S, Michy T, Fondrinier E, Butarelli M, Loustalot C, Raout I, Macgrogan G. P4-18-02: Sentinel Node Biopsy in Extensive Ductal Carcinoma In Situ (DCIS) Diagnosed by Vacuum-Assisted Macrobiopsy (VAMB) and Treated by Mastectomy: Results of the French Prospective Trial CINNAMOME. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-18-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Lymph node evaluation in the management of DCIS has been completely abandoned as a result of the documented low incidence of nodal metastases (<2%) and the significant morbidity of lymph node dissection. However, the risk of occult invasive disease exists when the initial diagnosis is performed by vacuum-assisted micro biopsy (VAMB). Invasive disease is usually discovered during the histological analyses following mastectomy. After mastectomy, the only option for patients is complete axillary lymph node dissection (ALND). The aim of this study was to evaluate the number of ALND that can be avoided by using the sentinel lymph node (SLN) procedure to identify patients with invasive disease but no SLN involvement.
Trial design: Patients with extensive microcalcifications on mammography and DCIS diagnosed by VAMB treated by mastectomy were included in the study. The SLN procedure was performed and intraoperative evaluation on frozen sections was carried out. If the SLN was positive an ALND was performed during the same intervention. If the SLN procedure failed or was negative an ALND was not performed. Radiography of the mastectomy specimen was performed to assist the pathologist in confirming the DCIS diagnosis, to evaluate the size and to determine concordance rates between initial VAMB diagnosis and histological analyses. Results: Fourteen French cancer centers took part in this protocol over 2 years (May 2008-December 2010). 228 patients were enrolled, including 197 DCIS on VAMB. The SLN was identified in 193 cases (98%) but one case was not documented at histology leaving 192 valid cases for analysis.
Distribution of SLN results and histological lesions found on mastectomy specimens in the series
ALND was not performed for non-invasive disease and negative SLN (n=114) and invasive or micro-invasive disease and negative SLN (n=51). This meant that ALND was avoided for 67.1% of the patients with invasive disease (51/76, 95%CI[56.5−77.7]), or 26.6% of patients overall (95%CI [20.3−32.8]), whereas these patients would have previously received ALND without the use of the SLN procedure. We observed 39.6% (76/192) of discordance between VAMB results and definitive results from histology analysis after mastectomy across all patients.
Conclusions: SLN is a useful procedure for patients with DCIS diagnosed by VAMB treated by mastectomy and presenting extensive microcalcifications on mammography. For patients for whom microinvasive or invasive carcinoma is later identified on the mastectomy specimen, the use of this procedure makes it possible to spare over a quarter of them from ALND and the associated morbidity. Biological analyses are currently underway to determine predictive factors of invasive disease associated with DCIS.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-18-02.
Collapse
Affiliation(s)
- C Tunon-de-lara
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - S Giard
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - M Baron
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - G Le-Bouedec
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - J-R Garbay
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - J Blanchot
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - J Mollard
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - H Charitansky
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | | | - T Michy
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - E Fondrinier
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - M Butarelli
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - C Loustalot
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - I Raout
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - G Macgrogan
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| |
Collapse
|
28
|
Hamidou Z, Dabakuyo TS, Mercier M, Fraisse J, Causeret S, Tixier H, Padeano MM, Loustalot C, Cuisenier J, Sauzedde JM, Smail M, Combier JP, Chevillote P, Rosburger C, Arveux P, Bonnetain F. Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancer. Oncologist 2011; 16:1458-68. [PMID: 21948650 DOI: 10.1634/theoncologist.2011-0085] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
PURPOSE This prospective multicenter study explored different definitions of time to deterioration (TTD) in quality of life (QoL) scores, according to different cutoffs of the minimal clinically important difference (MCID) as a modality for longitudinal QoL assessment in breast cancer patients. METHODS QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and BR-23 before surgery, after surgery, and 6 and 12 months later. The global health score, arm symptoms score (BRAS), and breast symptoms score were analyzed. For a given baseline score, QoL was considered to have deteriorated if this score decreased by ≥5 points at any time point after baseline. Analyses were repeated using an MCID of 10 points and taking the score after surgery as the reference score (to explore the occurrence of response shift). TTD was calculated using the Kaplan-Meier method and Cox regression was used to identify independent factors associated with TTD. RESULTS Two hundred thirty-five patients underwent axillary lymph node dissection (ALND), 222 underwent sentinel lymph node biopsy (SLNB), and 61 underwent SLNB plus ALND. Patients who underwent SLNB had a significantly longer TTD for the BRAS dimension than those who underwent ALND. Cox multivariate analyses showed that treatment using SLNB and age >59 years were independently associated with longer TTD for the BRAS, whereas surgery elsewhere than at the Centre Georges François Leclerc was associated with a shorter TTD. CONCLUSION Exploration of different definitions of TTD in QoL provides meaningful longitudinal QoL results for clinicians.
Collapse
Affiliation(s)
- Zeinab Hamidou
- Unité de Biostatistiques et d’Épidémiologie, Centre Georges Franc¸ois Leclerc, Dijon, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, Tomlinson G, Olopade OI, Couch FJ, Wang X, Lindor NM, Pankratz VS, Radice P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Viel A, Allavena A, Dall'Olio V, Peterlongo P, Szabo CI, Zikan M, Claes K, Poppe B, Foretova L, Mai PL, Greene MH, Rennert G, Lejbkowicz F, Glendon G, Ozcelik H, Andrulis IL, Thomassen M, Gerdes AM, Sunde L, Cruger D, Birk Jensen U, Caligo M, Friedman E, Kaufman B, Laitman Y, Milgrom R, Dubrovsky M, Cohen S, Borg A, Jernström H, Lindblom A, Rantala J, Stenmark-Askmalm M, Melin B, Nathanson K, Domchek S, Jakubowska A, Lubinski J, Huzarski T, Osorio A, Lasa A, Durán M, Tejada MI, Godino J, Benitez J, Hamann U, Kriege M, Hoogerbrugge N, van der Luijt RB, van Asperen CJ, Devilee P, Meijers-Heijboer EJ, Blok MJ, Aalfs CM, Hogervorst F, Rookus M, Cook M, Oliver C, Frost D, Conroy D, Evans DG, Lalloo F, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Hodgson S, Morrison PJ, Porteous ME, Walker L, Kennedy MJ, Dorkins H, Peock S, Godwin AK, Stoppa-Lyonnet D, de Pauw A, Mazoyer S, Bonadona V, Lasset C, Dreyfus H, Leroux D, Hardouin A, Berthet P, Faivre L, Loustalot C, Noguchi T, Sobol H, Rouleau E, Nogues C, Frénay M, Vénat-Bouvet L, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D, Singer CF, Dressler AC, Gschwantler-Kaulich D, Pfeiler G, Hansen TVO, Jønson L, Agnarsson BA, Kirchhoff T, Offit K, Devlin V, Dutra-Clarke A, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov E, Tihomirova L, Blanco I, Lazaro C, Ramus SJ, Sucheston L, Karlan BY, Gross J, Schmutzler R, Wappenschmidt B, Engel C, Meindl A, Lochmann M, Arnold N, Heidemann S, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Kast K, Schönbuchner I, Caldes T, de la Hoya M, Aittomäki K, Nevanlinna H, Simard J, Spurdle AB, Holland H, Chen X, Platte R, Chenevix-Trench G, Easton DF. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 2010; 70:9742-54. [PMID: 21118973 DOI: 10.1158/0008-5472.can-10-1907] [Citation(s) in RCA: 148] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The known breast cancer susceptibility polymorphisms in FGFR2, TNRC9/TOX3, MAP3K1, LSP1, and 2q35 confer increased risks of breast cancer for BRCA1 or BRCA2 mutation carriers. We evaluated the associations of 3 additional single nucleotide polymorphisms (SNPs), rs4973768 in SLC4A7/NEK10, rs6504950 in STXBP4/COX11, and rs10941679 at 5p12, and reanalyzed the previous associations using additional carriers in a sample of 12,525 BRCA1 and 7,409 BRCA2 carriers. Additionally, we investigated potential interactions between SNPs and assessed the implications for risk prediction. The minor alleles of rs4973768 and rs10941679 were associated with increased breast cancer risk for BRCA2 carriers (per-allele HR = 1.10, 95% CI: 1.03-1.18, P = 0.006 and HR = 1.09, 95% CI: 1.01-1.19, P = 0.03, respectively). Neither SNP was associated with breast cancer risk for BRCA1 carriers, and rs6504950 was not associated with breast cancer for either BRCA1 or BRCA2 carriers. Of the 9 polymorphisms investigated, 7 were associated with breast cancer for BRCA2 carriers (FGFR2, TOX3, MAP3K1, LSP1, 2q35, SLC4A7, 5p12, P = 7 × 10(-11) - 0.03), but only TOX3 and 2q35 were associated with the risk for BRCA1 carriers (P = 0.0049, 0.03, respectively). All risk-associated polymorphisms appear to interact multiplicatively on breast cancer risk for mutation carriers. Based on the joint genotype distribution of the 7 risk-associated SNPs in BRCA2 mutation carriers, the 5% of BRCA2 carriers at highest risk (i.e., between 95th and 100th percentiles) were predicted to have a probability between 80% and 96% of developing breast cancer by age 80, compared with 42% to 50% for the 5% of carriers at lowest risk. Our findings indicated that these risk differences might be sufficient to influence the clinical management of mutation carriers.
Collapse
Affiliation(s)
- Antonis C Antoniou
- Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Tixier H, Fraisse J, Chauffert B, Mayer F, Causeret S, Loustalot C, Deville C, Bonnetain F, Sagot P, Douvier S, Cuisenier J. Evaluation of pelvic posterior exenteration in the management of advanced-stage ovarian cancer. Arch Gynecol Obstet 2009; 281:505-10. [PMID: 19847452 DOI: 10.1007/s00404-009-1175-0] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2009] [Accepted: 06/25/2009] [Indexed: 01/11/2023]
Abstract
PURPOSE The main aim of this study was to show the interest of pelvic posterior exenteration to obtain complete resection of the tumor in case of invasion of the rectum by contiguity in advanced-stage ovarian cancer. The secondary aim was to determine the morbidity of this surgery. METHODS It is a multicentric, retrospective study of a series of 41 patients, who underwent posterior pelvectomy for advanced-stage ovarian cancer, over a period of 18 years, from July 1989 to July 2007. RESULTS The surgery resulted in macroscopically complete resection in 19 patients (46.34%), a residual tumor <2 cm in 19 patients (46.34%) and >2 cm in 3 patients (7.32%). In 34 patients (34/41), digestive continuity with satisfactory anal sphincter function was restored immediately or in the short term. The mean delay to the start of complementary treatment was 36 days. Median overall survival was 33 months. CONCLUSION The main aim of surgery for ovarian peritoneal carcinomatosis is to obtain a complete resection. In the case of direct invasion of the rectum by contiguity, when there is no cleavage plane between the uterus and the rectum, pelvic posterior exenteration is an effective method to achieve this objective. Morbidity is relatively high, but acceptable given the poor prognosis of this disease, the improved survival after surgery, and improvements in post-operative quality of life and functions.
Collapse
Affiliation(s)
- Hervé Tixier
- Department of Oncological Surgery, Georges François Leclerc Anticancer Center, 1, rue du Professeur Marion, 21000 Dijon, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Dabakuyo TS, Fraisse J, Causeret S, Gouy S, Padeano MM, Loustalot C, Cuisenier J, Sauzedde JM, Smail M, Combier JP, Chevillote P, Rosburger C, Boulet S, Arveux P, Bonnetain F. A multicenter cohort study to compare quality of life in breast cancer patients according to sentinel lymph node biopsy or axillary lymph node dissection. Ann Oncol 2009; 20:1352-61. [PMID: 19468032 DOI: 10.1093/annonc/mdp016] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND This prospective multicenter study assessed and compared the impact of different surgical procedures on quality of life (QoL) in breast cancer patients. PATIENTS AND METHODS The EORTC QLQ-C30 and the EORTC QLQ-BR-23 questionnaires were used to assess global health status (GHS), arm (BRAS) and breast (BRBS) symptom scales, before surgery, just after surgery and 6 and 12 months later. The Kruskal-Wallis test with the Bonferroni correction was used to compare scores. A mixed model analysis of variance for repeated measurements was then applied to assess the longitudinal effect of surgical modalities on QoL. RESULTS Before surgery, GHS (P = 0.7807) and BRAS (P = 0.7688) QoL scores were similar whatever the surgical procedure: sentinel node biopsy (SLNB), axillary node dissection (ALND) or SLNB + ALND. As compared with other surgical groups, GHS 75.91 [standard deviation (SD) = 17.44, P = 0.041] and BRAS 11.39 (SD = 15.36, P < 0.0001) were better in the SLNB group 12 months after surgery. Whatever the type of surgery, GHS decreased after surgery (P < 0.0001), but increased 6 months later (P = 0.0016). BRAS symptoms increased just after surgery (P = 0.0329) and until 6 months (P < 0.0001) before decreasing (P < 0.0001). CONCLUSIONS SLNB improved GHS and BRAS QoL in breast cancer patients. However, surgeons must be cautious, SLNB with ALND results in a poorer QoL.
Collapse
Affiliation(s)
- T S Dabakuyo
- Biostatistics and Epidemiology Unit, Medical Information Department, Centre Georges François Leclerc, Dijon, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Dabakuyo TS, Fraisse J, Causeret S, Gouy S, Padeano M, Loustalot C, Cuisenier J, Sauzedde J, Boulet S, Bonnetain F. A multicenter cohort to compare quality of life in breast cancer patients according to sentinel lymph node biopsy (SNLB) or full axillary clearance (AC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Dabakuyo TSM, Fraisse J, Causeret S, Gouy S, Padeano MM, Loustalot C, Cuisenier J, Sauzedde JM, Boulet S, Bonnetain F. Impact de la technique du ganglion sentinelle (SLNB) appliqué dans le cancer du sein en région Bourgogne. Rev Epidemiol Sante Publique 2008. [DOI: 10.1016/j.respe.2008.03.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Arnould L, Arveux P, Couturier J, Gelly-Marty M, Loustalot C, Ettore F, Sagan C, Antoine M, Penault-Llorca F, Vasseur B, Fumoleau P, Coudert BP. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res 2007; 13:6404-9. [PMID: 17975153 DOI: 10.1158/1078-0432.ccr-06-3022] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) are used to determine human epidermal growth factor receptor-2 (HER-2) status and patient eligibility for trastuzumab therapy. Using FISH and IHC, we analyzed the relationship between pathologic complete response to trastuzumab-based neoadjuvant therapy and level of HER-2 amplification in locally advanced breast cancer. EXPERIMENTAL DESIGN Breast biopsies from 93 HER-2-positive patients treated with trastuzumab-based neoadjuvant therapy were centrally collected and analyzed retrospectively for HER-2 amplification using FISH and HER-2 overexpression using IHC. Tumors were classified by FISH as no, low, or high amplification. Biopsies were reassessed centrally by IHC and graded 0, 1+, 2+, or 3+. RESULTS HER-2 status of tumor samples as assessed by FISH and IHC correlated: 16 no amplification (11 IHC 1+ and 5 IHC 2+), 27 low amplification (26 IHC 3+ and 1 IHC 2+), and 50 high amplification (all IHC 3+). Trastuzumab-based neoadjuvant therapy achieved pathologic complete response in 35 of 93 (37.6%) tumors. Pathologic complete response rate in low- and high-amplification tumors was significantly higher than in no-amplification tumors (44% versus 6%; P < 0.004). Pathologic complete response rate in high-amplification tumors was significantly higher compared with low-amplification tumors (56% versus 22%; P < 0.005). In the subgroup of low- plus high-amplification tumors, no correlation was found between pathologic complete response rate and IHC score, treatment regimen, T or N stage, tumor grade, or hormonal receptors. CONCLUSIONS This is the first study to show positive correlation between level of HER-2 amplification assessed by FISH and rate of pathologic complete response to trastuzumab-based neoadjuvant treatment.
Collapse
|
35
|
Bardou M, Rouget C, Breuiller-Fouché M, Loustalot C, Naline E, Sagot P, Frydman R, Morcillo EJ, Advenier C, Leroy MJ, Morrison JJ. Is the beta3-adrenoceptor (ADRB3) a potential target for uterorelaxant drugs? BMC Pregnancy Childbirth 2007; 7 Suppl 1:S14. [PMID: 17570158 PMCID: PMC1892055 DOI: 10.1186/1471-2393-7-s1-s14] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
The management of premature birth still remains unsatisfactory. Since the relative lack of efficiency and/or safety of current tocolytic agents have been highlighted, it is necessary to develop new uterorelaxant drugs deprived of important maternal and foetal side effects. Our work reported in this review focuses on a potential new target for tocolytic drugs, the β3-adrenoceptor (ADRB3). This third type of ADRB is shown to be present and functional in human myometrium. We demonstrated that ADRB3 agonists are able to inhibit in-vitro spontaneous contractions of myometrial strips, via a cyclic AMP-mediated pathway. Furthermore, we established that ADRB3 is the predominant subtype over the ADRB2 in human myometrium and that its expression is increased in near-term myometrium, compared to non-pregnant myometrium. Finally, we reported that contrary to ADRB2, the human myometrial ADRB3 is resistant to long-term agonist-induced desensitisation. These compelling data confirm the clinical potential interest of ADRB3 agonists in the pharmacological management of preterm labour.
Collapse
Affiliation(s)
- Marc Bardou
- Laboratoire de Physiologie et Pharmacologie Cardiovasculaires Expérimentales, Faculté de Médecine, Université de Bourgogne, Dijon Cedex, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Rouget C, Bardou M, Breuiller-Fouché M, Loustalot C, Qi H, Naline E, Croci T, Cabrol D, Advenier C, Leroy MJ. Beta3-adrenoceptor is the predominant beta-adrenoceptor subtype in human myometrium and its expression is up-regulated in pregnancy. J Clin Endocrinol Metab 2005; 90:1644-50. [PMID: 15585565 DOI: 10.1210/jc.2004-0233] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
To assess whether pregnancy might influence the functionality and expression of human myometrial beta(2)- and beta(3)-adrenoceptors (beta(2)- and beta(3)-AR), we performed functional, binding, Western blot, and molecular biology experiments in human nonpregnant and near-term pregnant myometrium. Inhibition of spontaneous contractions induced by a beta(3)-AR agonist, SR 59119A, was significantly greater in pregnant, compared with nonpregnant, myometrial strips (E'(max) = 61 +/- 5% vs. 44 +/- 5% for pregnant and nonpregnant myometrium, respectively), whereas salbutamol, a beta(2)-AR agonist, was significantly less efficient in pregnant, compared with nonpregnant, myometrium (E(max) = 29 +/- 4 vs. 54 +/- 8%). Although two populations of binding sites corresponding to beta(2)- and beta(3)-AR were identified in both nonpregnant and pregnant myometrium, we found a clear predominance of the beta(3)-AR subtype. Moreover, beta(3)-AR binding sites were up-regulated 2-fold in myometrium at the end of pregnancy. Both beta(2)- and beta(3)-AR mRNA were expressed in human nonpregnant and pregnant myometrium. Contrary to beta(2)-AR, the expression of the beta(3)-AR transcripts and immunoreactive proteins was increased in pregnant, compared with nonpregnant, myometrium. Such compelling data suggest a predominant role for beta(3)-AR in the regulation of human myometrium contractility, especially at the end of pregnancy, which might have important consequences for the clinical management of preterm labor.
Collapse
Affiliation(s)
- C Rouget
- Unité Propre de Recherche de l'Enseignement Supérieur EA220-Pharmacology, Unité de Formation et de Recherche Biomédicale des Saints Pères, 45 rue des Saints Pères, F-75006 Paris, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Rouget C, Breuiller-Fouché M, Mercier FJ, Leroy MJ, Loustalot C, Naline E, Frydman R, Croci T, Morcillo EJ, Advenier C, Bardou M. The human near-term myometrial beta 3-adrenoceptor but not the beta 2-adrenoceptor is resistant to desensitisation after sustained agonist stimulation. Br J Pharmacol 2004; 141:831-41. [PMID: 14769781 PMCID: PMC1574252 DOI: 10.1038/sj.bjp.0705616] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
1. In order to compare the beta(2)- and beta(3)-adrenoceptor (beta-AR) desensitisation process in human near-term myometrium, we examined the influence of a pretreatment of myometrial strips with either a beta(2)- or a beta(3)-AR agonist (salbutamol or SR 59119A, respectively, both at 10 microm, for 5 and 15 h) on the relaxation and the cyclic adenosine monophosphate (cAMP) production induced by these agonists. 2. To assess some of the mechanisms potentially implicated in the beta-AR desensitisation process, we studied the influence of such treatment on the number of beta(2)- and beta(3)-AR binding sites, the beta(2)- and beta(3)-AR transcripts expression and the phosphodiesterase 4 (PDE4) activity. 3. Salbutamol, but not SR 59119A, concentration-response curve (CRC) was shifted by a 15 h salbutamol preincubation, with a significant difference in -log EC(20) values (6.31+/-0.13 vs 5.58+/-0.24, for control and 15 h salbutamol pretreatment, respectively, P<0.05). Neither salbutamol nor SR 59119A CRCs were modified after a 15 h preincubation with SR 59119A. 4. A 15 h exposure of myometrial strips to salbutamol significantly reduced the salbutamol-induced (0.60+/-0.26 vs 1.54+/-0.24 pmol mg(-1) protein, P<0.05), but not the SR 59119A-induced, cAMP production. No decrease in cAMP production was observed after a 15 h SR 59119A exposure. 5. A 15 h salbutamol exposure of myometrial strips significantly reduced the beta(2)- but not the beta(3)-AR binding site density, whereas no decrease in the number of beta(2)- and beta(3)-AR binding sites was observed after a 15 h SR 59119A treatment. 6. Neither PDE4 activity nor the beta(2)- and beta(3)-AR mRNA expression levels were affected by salbutamol or SR 59119A treatments. 7. Our results indicate that beta(3)-AR, but not beta(2)-AR, are resistant to the agonist-induced desensitisation. In our model, beta(2)-AR desensitisation is mediated by a decreased number of beta(2)-AR that was not explained by transcriptional regulation of the receptor.
Collapse
Affiliation(s)
- C Rouget
- UPRES EA220-Pharmacology, UFR Biomédicale des Saints Pères, 45 rue des Saints Pères, Paris 75006, France
- INSERM U361, Pavillon Baudelocque, 123 Bd de Port-Royal, Paris 75014, France
- Author for correspondence:
| | - M Breuiller-Fouché
- INSERM U361, Pavillon Baudelocque, 123 Bd de Port-Royal, Paris 75014, France
| | - F J Mercier
- UPRES EA220-Pharmacology, UFR Biomédicale des Saints Pères, 45 rue des Saints Pères, Paris 75006, France
- Department of Anaesthesiology at CHU Antoine Béclère, 157 rue de la Porte de Trivaux, Clamart 92141, France
| | - M J Leroy
- INSERM U361, Pavillon Baudelocque, 123 Bd de Port-Royal, Paris 75014, France
| | - C Loustalot
- Department of Gynaecology CHU du Bocage, 21 Bd de Lattre de Tassigny, BP 1542, Dijon 21000, France
| | - E Naline
- UPRES EA220-Pharmacology, UFR Biomédicale des Saints Pères, 45 rue des Saints Pères, Paris 75006, France
| | - R Frydman
- Department of Gynaecology at CHU Antoine Béclère, 157 rue de la Porte de Trivaux, Clamart 92141, France
| | - T Croci
- Research Centre Sanofi-Midy, Via Piranesi, 38, Milan 20137, Italy
| | - E J Morcillo
- Department of Pharmacology, University of Valencia, Av. Blasco Ibañez 17, Valencia 46010, Spain
| | - C Advenier
- UPRES EA220-Pharmacology, UFR Biomédicale des Saints Pères, 45 rue des Saints Pères, Paris 75006, France
| | - M Bardou
- UPRES EA220-Pharmacology, UFR Biomédicale des Saints Pères, 45 rue des Saints Pères, Paris 75006, France
- Laboratory of Cardiovascular Physiopathology and Pharmacology, Faculty of Medicine, 7 Bd Jeanne d'Arc, BP 87900, Dijon 21079, France
- Author for correspondence:
| |
Collapse
|
38
|
Bardou M, Loustalot C, Simon B, Morcillo E, Croci T, Advenier C. [Inhibition of uterine contractions: new in vitro pharmacological approaches on the pregnant human myometrium]. Therapie 2001; 56:213-22. [PMID: 11475797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
The aim of this study was to evaluate the in vitro effects of phosphodiesterase 4 inhibitors (PDE4I) and their combination with salbutamol (beta 2-adrenoceptor agonist) on spontaneous contractions and to investigate by in vitro and biochemical studies and analysis of mRNA expression the presence of beta 3-adrenoceptor in human near-term myometrium. Rolipram, RP 73401 and Ro 20-1724 (PDE4I) inhibited spontaneous myometrial contractions (Emax approximately 100 per cent; pD2 approximately 6.80 for the two first and 6.31 for Ro 20-1724). Rolipram 10(-8) M potentiated the response to salbutamol (Emax = 88 per cent vs. 40 per cent and pD2 = 6.93 and 6.36 with or without rolipram respectively). SR 59119A, a beta 3-adrenoceptor agonist, was more efficient than salbutamol in inhibiting the contractions (Emax 52 per cent and 27 per cent respectively, p < 0.05) but they both induced a significant increase of cAMP production. In both functional and biochemical studies, SR 59119A was only antagonized by the beta 3-adrenoceptor antagonist SR 59230A. The beta 3-AR mRNA was positively expressed in myometrium preparations in a reverse transcription polymerase chain assay. In conclusion, phosphodiesterase 4 inhibitors alone or combined with beta 2-adrenoceptor agonists and beta 3-adrenoceptor agonists might have potential interest as tocolytic agents.
Collapse
Affiliation(s)
- M Bardou
- LPPCE, Faculté de Médecine, 7 bd Jeanne d'Arc, BP 87900, 21079 Dijon, France
| | | | | | | | | | | |
Collapse
|
39
|
Bardou M, Loustalot C, Cortijo J, Simon B, Naline E, Dumas M, Esteve S, Croci T, Chalon P, Frydman R, Sagot P, Manara L, Morcillo EJ, Advenier C. Functional, biochemical and molecular biological evidence for a possible beta(3)-adrenoceptor in human near-term myometrium. Br J Pharmacol 2000; 130:1960-6. [PMID: 10952688 PMCID: PMC1572258 DOI: 10.1038/sj.bjp.0703491] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
The possible existence of a beta(3)-adrenoceptor (beta(3)-AR) in human near-term myometrium was investigated by in vitro functional and biochemical studies and analysis of mRNA expression. SR 59119A and SR 59104A and CGP 12177 (two selective agonists and a partial agonist, respectively, of the beta(3)-AR), salbutamol and terbutaline (beta(2)-AR agonists) each produced a concentration-dependent relaxation of the myometrial spontaneous contractions. There were no differences in pD(2) values for the relaxing potencies of terbutaline, salbutamol, CGP 12177 and SR 59119A. The rank order for their relaxing efficacies was SR 59119A>SR 59104A>terbutaline approximately salbutamol approximately CGP 12177 (E(max)=52+/-7%, 42+/-12% and approximately 30% respectively). Propranolol, a beta(1)- and beta(2)-AR antagonist, and ICI 118551, a beta(2)-AR antagonist (both at 0.1 microM), did not affect the SR 59119A-induced relaxation whereas SR 59230A, a selective beta(3)-AR antagonist (1 microM), significantly reduced the maximal relaxing effect of SR 59119A. SR 59119A and salbutamol induced a significant increase in cyclic AMP levels that was antagonized by SR 59230A but not by propranolol for SR 59119A, and by propranolol but not by SR 59230A for salbutamol. The beta(3)-AR mRNA was positively expressed in myometrium preparations in a reverse transcription polymerase chain assay. The results presented provide the first evidence for the existence of the beta(3)-AR subtype in human near-term myometrium and suggest that the effects of SR 59119A might be mediated through an increase in cyclic AMP level.
Collapse
Affiliation(s)
- M Bardou
- Department of Pharmacology, Faculty of Medicine Paris-Ouest, 15 rue de l'Ecole de Médecine 75006 Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Bardou M, Cortijo J, Loustalot C, Taylor S, Perales-Marín A, Mercier FJ, Dumas M, Deneux-Tharaux C, Frydman R, Morcillo EJ, Advenier C. Pharmacological and biochemical study on the effects of selective phosphodiesterase inhibitors on human term myometrium. Naunyn Schmiedebergs Arch Pharmacol 1999; 360:457-63. [PMID: 10551283 DOI: 10.1007/s002109900092] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
This study was aimed at evaluating the in vitro effects of phosphodiesterase inhibitors and beta2-adrenoceptor agonists on spontaneous contractions of human term myometrium. Rolipram, RP 73401 (3-cyclopentyloxy-N-(3,5(-dichloro-4-pyridil)-4-methoxybenzamide) and Ro 20-1724 (1-4-(3-butoxy-4-methoxybenzyl)-2-imidozolidinone) (phosphodiesterase 4 inhibitors) inhibited spontaneous myometrial contractions (Emax approximately 100%; pD2 of 6.80+/-0.28, 6.84+/-0.32 and 6.31+/-0.03, respectively). Salbutamol and formoterol were less effective (Emax=40+/-6% and 35+/-12%, respectively) than phosphodiesterase 4 inhibitors to reduce myometrial contractility. Inhibitors of phosphodiesterase 3 (milrinone and siguazodan) and 5 (zaprinast) were marginally effective. Rolipram (10-30 nM) and siguazodan (0.1 microM) potentiated the response to salbutamol (Emax=75+/-12%, 88+/-8% and 73+/-12% and pD2=6.51+/-0.20, 6.93+/-0.29 and 6.48+/-0.16, respectively). Sodium nitroprusside (pD2=6.76+/-0.29) and theophylline (pD2=5.15+/-0.22) were effective inhibitors of myometrial contractions. Chromatographic separation of phosphodiesterase isoenzymes demonstrated that phosphodiesterase 4 is predominant but other phosphodiesterase isoenzymes were also identified. In conclusion, phosphodiesterase 4 inhibitors alone or combined with beta2-adrenoceptor agonists have potential interest as tocolytic agents.
Collapse
Affiliation(s)
- M Bardou
- Department of Pharmacology, Faculty of Medicine Paris-Ouest, Paris, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|